{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:23:04Z","timestamp":1790922184575,"version":"4.1.0"},"reference-count":508,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Bioactive natural products (NPs) may play a critical role in cancer progression by targeting nucleic acids and a wide array of proteins, including enzymes. Furthermore, a large number of derivatives (NPDs), including semi-synthetic products and pharmacophores from NPs, have been developed to enhance the solubility and stability of NPs. Acute myeloid leukemia (AML) is a poor-prognosis hematologic malignancy characterized by the clonal accumulation in the blood and bone marrow of myeloid progenitors with high proliferative capacity, survival and propagation abilities. A number of potential pathways and targets have been identified for development in AML, and include, but are not limited to, Fms-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenases resulting from genetic mutations, BCL2 family members, various signaling kinases and histone deacetylases, as well as tumor-associated antigens (such as CD13, CD33, P-gp). By targeting nucleic acids, FLT3 or CD33, several FDA-approved NPs and NPDs (i.e., cytarabine, anthracyclines, midostaurin, melphalan and calicheamicin linked to anti-CD33) are the major agents of upfront treatment of AML. However, the effective treatment of the disease remains challenging, in part due to the heterogeneity of the disease but also to the involvement of the bone marrow microenvironment and the immune system in favoring leukemic stem cell persistence. This review summarizes the current state of the art, and provides a summary of selected NPs\/NPDs which are either entering or have been investigated in preclinical and clinical trials, alone or in combination with current chemotherapy. With multifaceted actions, these biomolecules may target all hallmarks of AML, including multidrug resistance and deregulated metabolism.<\/jats:p>","DOI":"10.3390\/cancers18020185","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:35:47Z","timestamp":1767702947000},"page":"185","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Implementation of Natural Products and Derivatives in Acute Myeloid Leukemia Management: Current Treatments, Clinical Trials and Future Directions"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4601-1998","authenticated-orcid":false,"given":"Faten","family":"Merhi","sequence":"first","affiliation":[{"name":"Department of Life & Earth Sciences, Faculty of Sciences (I), Lebanese University, Beirut P.O. Box 14-6573, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9014-0283","authenticated-orcid":false,"given":"Daniel","family":"Dauzonne","sequence":"additional","affiliation":[{"name":"Institut Curie, D\u00e9partement Recherche, CNRS UMR3666, Inserm U1339, 75005 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1751-6922","authenticated-orcid":false,"given":"Brigitte","family":"Bauvois","sequence":"additional","affiliation":[{"name":"Centre de Recherche des Cordeliers, Sorbonne Universit\u00e9, Universit\u00e9 Paris Cit\u00e9, Inserm UMRS 1138, Drug Resistance in Hematological Malignancies Team, 75006 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000536152","article-title":"Pathophysiology of Acute Myeloid Leukemia","volume":"147","author":"Wachter","year":"2024","journal-title":"Acta Haematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.tips.2024.03.005","article-title":"AML treatment: Conventional chemotherapy and emerging novel agents","volume":"45","author":"Forsberg","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_3","first-page":"46","article-title":"Acute myeloid leukemia management and research in 2025","volume":"75","author":"Kantarjian","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"395","DOI":"10.23736\/S0026-4806.20.07019-6","article-title":"Gemtuzumab ozogamicin in acute myeloid leukemia: Past, present and future","volume":"111","author":"Gottardi","year":"2020","journal-title":"Minerva Medica"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"215603","DOI":"10.1016\/j.canlet.2022.215603","article-title":"Resistance to mutant IDH inhibitors in acute myeloid leukemia: Molecular mechanisms and therapeutic strategies","volume":"533","author":"Yao","year":"2022","journal-title":"Cancer Lett."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"100905","DOI":"10.1016\/j.blre.2021.100905","article-title":"A review of FLT3 inhibitors in acute myeloid leukemia","volume":"52","author":"Zhao","year":"2022","journal-title":"Blood Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/bmt.2016.251","article-title":"Inhibition of FLT3 in AML: A focus on sorafenib","volume":"52","author":"Antar","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-020-01069-1","article-title":"New strategies to treat AML: Novel insights into AML survival pathways and combination therapies","volume":"35","author":"Nair","year":"2021","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-020-00114-z","article-title":"Natural products in drug discovery: Advances and opportunities","volume":"20","author":"Atanasov","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.phytol.2024.01.001","article-title":"Exploring the potential of marine natural products in drug development: A comprehensive review","volume":"59","author":"Banday","year":"2024","journal-title":"Phytochem. Lett."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1007\/s00204-024-03786-3","article-title":"The Emerging Role of Natural Products in Cancer Treatment","volume":"98","author":"Ghosh","year":"2024","journal-title":"Arch. Toxicol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"10757","DOI":"10.1021\/acs.joc.7b01368","article-title":"Natural Products and Their Mimics as Targets of Opportunity for Discovery","volume":"82","author":"Martin","year":"2017","journal-title":"J. Org. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Naeem, A., Hu, P., Yang, M., Zhang, J., Liu, Y., Zhu, W., and Zheng, Q. (2022). Natural Products as Anticancer Agents: Current Status and Future Perspectives. Molecules, 27.","DOI":"10.3390\/molecules27238367"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.2174\/1389450121999201230204526","article-title":"Natural Products as Anticancer Agents","volume":"22","author":"Varghese","year":"2020","journal-title":"Curr. Drug Targets"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1111\/bph.16232","article-title":"Natural products targeting tumour angiogenesis","volume":"182","author":"Lu","year":"2025","journal-title":"Br. J. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1055\/s-2003-45141","article-title":"Anti-inflammatory compounds of plant origin. Part I. Action on arachidonic acid pathway, nitric oxide and nuclear factor kappa B (NF-kappaB)","volume":"69","author":"Calixto","year":"2003","journal-title":"Planta Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1055\/s-2004-815483","article-title":"Anti-inflammatory compounds of plant origin. Part II. modulation of pro-inflammatory cytokines, chemokines and adhesion molecules","volume":"70","author":"Calixto","year":"2004","journal-title":"Planta Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2006.09.002","article-title":"Myeloid cell trafficking and tumor angiogenesis","volume":"250","author":"Schmid","year":"2007","journal-title":"Cancer Lett."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1179\/1607845413Y.0000000139","article-title":"Angiogenesis and acute myeloid leukemia","volume":"19","author":"Haouas","year":"2014","journal-title":"Hematology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.bbrc.2023.09.023","article-title":"HDAC inhibitors: Promising agents for leukemia treatment","volume":"680","author":"Deng","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Urwanisch, L., Unger, M.S., Sieberer, H., Dang, H.H., Neuper, T., Regl, C., Vetter, J., Schaller, S., Winkler, S.M., and Kerschbamer, E. (2023). The Class IIA Histone Deacetylase (HDAC) Inhibitor TMP269 Downregulates Ribosomal Proteins and Has Anti-Proliferative and Pro-Apoptotic Effects on AML Cells. Cancers, 15.","DOI":"10.3390\/cancers15041039"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/sj.leu.2404245","article-title":"Phosphoinositide 3-kinase\/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia","volume":"20","author":"Martelli","year":"2006","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"192","DOI":"10.18632\/aging.100296","article-title":"Roles of the Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging","volume":"3","author":"Steelman","year":"2011","journal-title":"Aging"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.blre.2016.02.001","article-title":"Update on rational targeted therapy in AML","volume":"30","author":"Shafer","year":"2016","journal-title":"Blood Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood-2003-06-1845","article-title":"Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia","volume":"103","author":"Ozeki","year":"2004","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1152\/physiolgenomics.00173.2013","article-title":"Rational combination of dual PI3K\/mTOR blockade and Bcl-2\/-xL inhibition in AML","volume":"46","author":"Vachhani","year":"2014","journal-title":"Physiol. Genom."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1111\/febs.16136","article-title":"Understanding MCL1: From cellular function and regulation to pharmacological inhibition","volume":"289","author":"Sancho","year":"2022","journal-title":"FEBS J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1034\/j.1600-0609.2001.t01-1-00385.x","article-title":"Constitutive activation of STAT transcription factors in acute myelogenous leukemia","volume":"67","author":"Spiekermann","year":"2001","journal-title":"Eur. J. Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3324\/haematol.2009.013797","article-title":"Role of the PI3K\/AKT and mTOR signaling pathways in acute myeloid leukemia","volume":"95","author":"Park","year":"2010","journal-title":"Haematologica"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41375-021-01440-w","article-title":"Correction: PI3-kinase\/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kB, MAPkinase and p53 pathways","volume":"36","author":"Grandage","year":"2022","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"39784","DOI":"10.18632\/oncotarget.9289","article-title":"Targeting PI3K\u03b4 and PI3K\u03b3 signalling disrupts human AML survival and bone marrow stromal cell mediated protection","volume":"7","author":"Pillinger","year":"2016","journal-title":"Oncotarget"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Di Francesco, B., Verzella, D., Capece, D., Vecchiotti, D., Di Vito Nolfi, M., Flati, I., Cornice, J., Di Padova, M., Angelucci, A., and Alesse, E. (2022). NF-\u03baB: A Druggable Target in Acute Myeloid Leukemia. Cancers, 14.","DOI":"10.3390\/cancers14143557"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1182\/blood.V98.8.2301","article-title":"Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells","volume":"98","author":"Guzman","year":"2001","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/sj.leu.2402641","article-title":"Increased IkappaB kinase activity is associated with activated NF-kappaB in acute myeloid blasts","volume":"16","author":"Baumgartner","year":"2002","journal-title":"Leukemia"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.critrevonc.2015.10.001","article-title":"Constitutive NF-\u03baB activation in AML: Causes and treatment strategies","volume":"98","author":"Bosman","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"666","DOI":"10.4149\/neo_2013_085","article-title":"Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: Its correlation with FLT3","volume":"60","author":"Mehta","year":"2013","journal-title":"Neoplasma"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4252\/wjsc.v10.i4.34","article-title":"NF-\u03baB promotes the stem-like properties of leukemia cells by activation of LIN28B","volume":"10","author":"Zhou","year":"2018","journal-title":"World J. Stem Cells"},{"key":"ref_38","first-page":"7","article-title":"Roles of STAT3 in leukemia (Review)","volume":"53","author":"Shi","year":"2018","journal-title":"Int. J. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1182\/blood-2013-05-505735","article-title":"Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells","volume":"123","author":"Cook","year":"2014","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1182\/blood-2023-179453","article-title":"Mitochondrial STAT3 Plays a Critical Role in Survival of AML Cells","volume":"142","author":"Gil","year":"2023","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3892\/ol.2025.14881","article-title":"Advances of signal transducer and activator of transcription 3 inhibitors in acute myeloid leukemia (Review)","volume":"29","author":"Cheng","year":"2025","journal-title":"Oncol. Lett."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1182\/blood.2021013201","article-title":"The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation","volume":"139","author":"Amaya","year":"2022","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1038\/sj.leu.2401605","article-title":"Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics","volume":"13","author":"Wuchter","year":"1999","journal-title":"Leukemia"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Wei, Y., Cao, Y., Sun, R., Cheng, L., Xiong, X., Jin, X., He, X., Lu, W., and Zhao, M. (2020). Targeting Bcl-2 Proteins in Acute Myeloid Leukemia. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.584974"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1101\/gad.182980.111","article-title":"Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia","volume":"26","author":"Glaser","year":"2012","journal-title":"Genes Dev."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1182\/blood.2020006785","article-title":"BCL2 and MCL1 inhibitors for hematologic malignancies","volume":"138","author":"Roberts","year":"2021","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1182\/blood-2008-12-196055","article-title":"FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation","volume":"114","author":"Yoshimoto","year":"2009","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood-2007-11-126664","article-title":"A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML","volume":"113","author":"Breitenbuecher","year":"2009","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1189\/jlb.70.1.11","article-title":"Transmembrane proteases in focus: Diversity and redundancy?","volume":"70","author":"Bauvois","year":"2001","journal-title":"J. Leukoc. Biol."},{"key":"ref_50","first-page":"211","article-title":"Myeloid enzymes profile related to the immunophenotypic characteristics of blast cells from patients with acute myeloid leukemia (AML) at diagnosis","volume":"52","author":"Klobusicka","year":"2005","journal-title":"Neoplasma"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood-2005-03-1072","article-title":"Hematopoietic stem cells express multiple myeloid markers: Implications for the origin and targeted therapy of acute myeloid leukemia","volume":"106","author":"Taussig","year":"2005","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"8211","DOI":"10.18632\/oncotarget.1788","article-title":"Targeting CD13 (aminopeptidase-N) in turn downregulates ADAM17 by internalization in acute myeloid leukaemia cells","volume":"5","author":"Bouchet","year":"2014","journal-title":"Oncotarget"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/med.20044","article-title":"Aminopeptidase-N\/CD13 (EC 3.4.11.2) inhibitors: Chemistry, biological evaluations, and therapeutic prospects","volume":"26","author":"Bauvois","year":"2006","journal-title":"Med. Res. Rev."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1096\/fj.11-181396","article-title":"Aminopeptidase-N\/CD13 is a potential proapoptotic target in human myeloid tumor cells","volume":"25","author":"Piedfer","year":"2011","journal-title":"FASEB J."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Liu, J., Tong, J., and Yang, H. (2022). Targeting CD33 for acute myeloid leukemia therapy. BMC Cancer, 22.","DOI":"10.1186\/s12885-021-09116-5"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"43281","DOI":"10.18632\/oncotarget.9674","article-title":"Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia","volume":"7","author":"Laszlo","year":"2016","journal-title":"Oncotarget"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1038\/bcj.2014.39","article-title":"Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia","volume":"4","author":"Ehninger","year":"2014","journal-title":"Blood Cancer J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1182\/blood-2011-12-398370","article-title":"Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML","volume":"119","author":"Pollard","year":"2012","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1182\/blood.V96.2.483.014k40_483_490","article-title":"Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2","volume":"96","author":"Paul","year":"2000","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0301-472X(03)00044-4","article-title":"The inhibitory effect of anti-CD33 monoclonal antibodies on AML cell growth correlates with Syk and\/or ZAP-70 expression","volume":"31","author":"Balaian","year":"2003","journal-title":"Exp. Hematol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1182\/blood.V91.9.3401","article-title":"A strong expression of CD44-6v correlates with shorter survival of patients with acute myeloid leukemia","volume":"91","author":"Legras","year":"1998","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.7314\/APJCP.2012.13.8.3791","article-title":"Prognostic significance of CD44v6\/v7 in acute promyelocytic leukemia","volume":"13","author":"Chen","year":"2012","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/leu.2010.281","article-title":"High levels of the adhesion molecule CD44 on leukemic cells generate acute myeloid leukemia relapse after withdrawal of the initial transforming event","volume":"25","author":"Andradottir","year":"2011","journal-title":"Leukemia"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3892\/ol.2015.3189","article-title":"Prognostic value of the expression of phosphatase and tensin homolog and CD44 in elderly patients with refractory acute myeloid leukemia","volume":"10","author":"Huang","year":"2015","journal-title":"Oncol. Lett."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.biomaterials.2013.11.011","article-title":"Differences between healthy hematopoietic progenitors and leukemia cells with respect to CD44 mediated rolling versus adherence behavior on hyaluronic acid coated surfaces","volume":"35","author":"Hanke","year":"2014","journal-title":"Biomaterials"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.3324\/haematol.2017.167304","article-title":"An extracellular matrix signature in leukemia precursor cells and acute myeloid leukemia","volume":"102","author":"Izzi","year":"2017","journal-title":"Haematologica"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.leukres.2011.09.022","article-title":"CD44 activation enhances acute monoblastic leukemia cell survival via Mcl-1 upregulation","volume":"36","author":"Sansonetti","year":"2012","journal-title":"Leuk. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/mc.22239","article-title":"Bone marrow stromal cells protect acute myeloid leukemia cells from anti-CD44 therapy partly through regulating PI3K\/Akt-p27(Kip1) axis","volume":"54","author":"Chen","year":"2015","journal-title":"Mol. Carcinog."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.3324\/haematol.2019.231944","article-title":"CD44 engagement enhances acute myeloid leukemia cell adhesion to the bone marrow microenvironment by increasing VLA-4 avidity","volume":"106","author":"Gutjahr","year":"2021","journal-title":"Haematologica"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"7406","DOI":"10.4081\/hr.2017.7406","article-title":"Expression of some ATP-binding cassette transporters in acute myeloid leukemia","volume":"9","author":"Salvia","year":"2017","journal-title":"Hematol. Rep."},{"key":"ref_71","first-page":"169","article-title":"ABCB1 genetic variants in leukemias: Current insights into treatment outcomes","volume":"10","author":"Ankathil","year":"2017","journal-title":"Pharmacogenom. Pers. Med."},{"key":"ref_72","first-page":"34","article-title":"P-glycoprotein and multidrug resistance associated protein-1 activity in 132 acute myeloid leukemias according to FAB subtypes and cytogenetics risk groups","volume":"89","author":"Legrand","year":"2004","journal-title":"Haematologica"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4615-4811-9_1","article-title":"MDR1\/P-GP expression as a prognostic factor in acute leukemias","volume":"457","author":"Marie","year":"1999","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_74","first-page":"163","article-title":"Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia","volume":"74","author":"Oliveira","year":"2008","journal-title":"Cytom. Part B Clin. Cytom."},{"key":"ref_75","first-page":"783","article-title":"P-glycoprotein expression and prognostic value in acute myeloid leukemia","volume":"83","author":"Senent","year":"1998","journal-title":"Haematologica"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1046\/j.1365-2141.1998.01111.x","article-title":"Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival","volume":"103","author":"Borg","year":"1998","journal-title":"Br. J. Haematol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Wang, X., Bove, A.M., Simone, G., and Ma, B. (2020). Molecular Bases of VEGFR-2-Mediated Physiological Function and Pathological Role. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.599281"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1182\/blood.V94.11.3717","article-title":"Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia","volume":"94","author":"Aguayo","year":"1999","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/sj.leu.2402534","article-title":"Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia","volume":"16","author":"Bieker","year":"2002","journal-title":"Leukemia"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/10428190500270386","article-title":"Disease-specific expression of VEGF and its receptors in AML cells: Possible autocrine pathway of VEGF\/type1 receptor of VEGF in t(15;17) AML and VEGF\/type2 receptor of VEGF in t(8;21) AML","volume":"47","author":"Hiramatsu","year":"2006","journal-title":"Leuk. Lymphoma"},{"key":"ref_81","first-page":"42","article-title":"The antiangiogenic phloroglucinol hyperforin inhibits the secretion of proMMP-2, proMMP-9 and VEGF-A during apoptosis of primary acute myeloid leukemia cells","volume":"7","author":"Merhi","year":"2021","journal-title":"J. Cancer Metastasis Treat."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1182\/blood.V97.5.1427","article-title":"Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes","volume":"97","author":"Bellamy","year":"2001","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1309\/331QX7AXKWFJFKXM","article-title":"Immunohistochemical detection of VEGF in the bone marrow of patients with acute myeloid leukemia. Correlation between VEGF expression and the FAB category","volume":"119","author":"Ghannadan","year":"2003","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_84","first-page":"5282","article-title":"Up-regulation of VEGF and its receptor in refractory leukemia cells","volume":"8","author":"Wang","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1172\/JCI8978","article-title":"Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration","volume":"106","author":"Dias","year":"2000","journal-title":"J. Clin. Investig."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1182\/blood.V99.7.2532","article-title":"VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition","volume":"99","author":"Dias","year":"2002","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1182\/blood-2003-05-1634","article-title":"Internal and external autocrine VEGF\/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways","volume":"103","author":"Santos","year":"2004","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/leu.2008.300","article-title":"The role of VEGF and a functional link between VEGF and p27Kip1 in acute myeloid leukemia","volume":"23","author":"Wegiel","year":"2009","journal-title":"Leukemia"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.leukres.2007.10.005","article-title":"Expression of VEGF-C and its receptor VEGFR-3 in the bone marrow of patients with acute myeloid leukaemia","volume":"32","author":"Liersch","year":"2008","journal-title":"Leuk. Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1093\/carcin\/bgp244","article-title":"Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3\/JNK\/AP-1 pathway","volume":"30","author":"Chien","year":"2009","journal-title":"Carcinogenesis"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s00018-012-1085-3","article-title":"Vascular endothelial growth factor signaling in acute myeloid leukemia","volume":"70","author":"Kampen","year":"2013","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1182\/blood-2010-03-270991","article-title":"High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia","volume":"116","author":"Valk","year":"2010","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1182\/blood.V99.6.2179","article-title":"Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy","volume":"99","author":"Dias","year":"2002","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.bbamcr.2013.10.015","article-title":"Vascular endothelial growth factor-C modulates proliferation and chemoresistance in acute myeloid leukemic cells through an endothelin-1-dependent induction of cyclooxygenase-2","volume":"1843","author":"Hua","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1182\/blood.V106.11.4293.4293","article-title":"Vascular Endothelial Growth Factor Contributes to Adverse Patient Outcome in Acute Myeloid Leukemia by Promoting Cell Growth and Survival and by Reducing the Sensitivities of Leukemic Cells to Drug-Induced Apoptosis","volume":"106","author":"Brunhoff","year":"2005","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.exphem.2005.03.009","article-title":"HSP27 protects AML cells against VP-16-induced apoptosis through modulation of p38 and c-Jun","volume":"33","author":"Schepers","year":"2005","journal-title":"Exp. Hematol."},{"key":"ref_97","first-page":"15","article-title":"Relationship between VEGF and MMP-2, MMP-9 in 82 patients with acute myeloid leukemia","volume":"14","author":"Yang","year":"2006","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/ijc.24386","article-title":"Enhanced invasiveness of drug-resistant acute myeloid leukemia cells through increased expression of matrix metalloproteinase-2","volume":"125","author":"Song","year":"2009","journal-title":"Int. J. Cancer"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1600-0609.2009.01382.x","article-title":"Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: Release profile and pharmacological modulation","volume":"84","author":"Reikvam","year":"2010","journal-title":"Eur. J. Haematol."},{"key":"ref_100","first-page":"29","article-title":"New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: Outside-in signaling and relationship to tumor progression","volume":"1825","author":"Bauvois","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.7314\/APJCP.2016.17.3.1519","article-title":"Secretion and Expression of Matrix Metalloproteinase-2 and 9 from Bone Marrow Mononuclear Cells in Myelodysplastic Syndrome and Acute Myeloid Leukemia","volume":"17","author":"Chaudhary","year":"2016","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Tolomeo, M., and Cascio, A. (2021). The Multifaced Role of STAT3 in Cancer and Its Implication for Anticancer Therapy. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020603"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3109\/10409238.2013.770819","article-title":"Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): The next decade","volume":"48","author":"Vandooren","year":"2013","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1182\/blood-2008-04-148643","article-title":"Role of leukemia cell invadosome in extramedullary infiltration","volume":"114","author":"Stefanidakis","year":"2009","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.leukres.2010.01.016","article-title":"The essential roles of matrix metalloproteinase-2, membrane type 1 metalloproteinase and tissue inhibitor of metalloproteinase-2 in the invasive capacity of acute monocytic leukemia SHI-1 cells","volume":"34","author":"Wang","year":"2010","journal-title":"Leuk. Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1182\/bloodadvances.2021004321","article-title":"Metalloproteinase inhibition reduces AML growth, prevents stem cell loss, and improves chemotherapy effectiveness","volume":"6","author":"Pirillo","year":"2022","journal-title":"Blood Adv."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4161\/cc.7.8.5645","article-title":"Cell-surface MMP-9 regulates the invasive capacity of leukemia blast cells with monocytic features","volume":"7","author":"Paupert","year":"2008","journal-title":"Cell Cycle"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s004320050161","article-title":"Expression of the active form of MMP-2 on the surface of leukemic cells accounts for their in vitro invasion","volume":"124","author":"Sawicki","year":"1998","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"119141","DOI":"10.1016\/j.bbamcr.2021.119141","article-title":"ADAM17 orchestrates Interleukin-6, TNF\u03b1 and EGF-R signaling in inflammation and cancer","volume":"1869","author":"Schumacher","year":"2022","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"ref_110","first-page":"252","article-title":"Baseline serum levels of multiple cytokines and adhesion molecules in patients with acute myeloid leukemia: Results of a pivotal trial","volume":"36","author":"Kupsa","year":"2014","journal-title":"Exp. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1182\/blood-2015-01-624833","article-title":"Transmembrane TNF-\u03b1 preferentially expressed by leukemia stem cells and blasts is a potent target for antibody therapy","volume":"126","author":"Zhou","year":"2015","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/blood.V122.21.2890.2890","article-title":"AML Cells Utilize TNF-Driven JNK Signaling As a Critical NF-\u03baB-Independent Survival Signal","volume":"122","author":"Volk","year":"2013","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.3892\/ol.2015.3786","article-title":"Inhibition of tumor necrosis factor-\u03b1 enhances apoptosis induced by nuclear factor-\u03baB inhibition in leukemia cells","volume":"10","author":"Dong","year":"2015","journal-title":"Oncol. Lett."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.exphem.2016.10.005","article-title":"Tumor necrosis factor \u03b1 in the onset and progression of leukemia","volume":"45","author":"Zhou","year":"2017","journal-title":"Exp. Hematol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"317","DOI":"10.18632\/oncotarget.163","article-title":"The heme oxygenase-1 and c-FLIP in acute myeloid leukemias: Two non-redundant but mutually exclusive cellular safeguards protecting cells against TNF-induced cell death?","volume":"1","author":"Shirley","year":"2010","journal-title":"Oncotarget"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1007\/s00018-013-1545-4","article-title":"NF-\u03baB pathways in hematological malignancies","volume":"71","author":"Gasparini","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1158\/1078-0432.CCR-10-3022","article-title":"A noncanonical Flt3ITD\/NF-\u03baB signaling pathway represses DAPK1 in acute myeloid leukemia","volume":"18","author":"Shanmugam","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1080\/14656566.2017.1391216","article-title":"Cytarabine and daunorubicin for the treatment of acute myeloid leukemia","volume":"18","author":"Murphy","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_119","first-page":"100272","article-title":"Treatment outcome of doxorubicin versus idarubicin in adult acute myeloid leukemia","volume":"16","author":"Sherif","year":"2021","journal-title":"Leuk. Res. Rep."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3324\/haematol.2021.280161","article-title":"The \u201c7+3\u201d regimen in acute myeloid leukemia","volume":"107","author":"Rowe","year":"2022","journal-title":"Haematologica"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.2147\/IJN.S139450","article-title":"CPX-351: A nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties","volume":"14","author":"Mayer","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3324\/haematol.2022.280798","article-title":"New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia","volume":"108","author":"Mohty","year":"2023","journal-title":"Haematologica"},{"key":"ref_123","first-page":"e70199","article-title":"The Clinical Safety and Efficacy of Cytarabine and Daunorubicin Liposome (CPX-351) in Acute Myeloid Leukemia Patients: A Systematic Review","volume":"8","author":"Alzahrani","year":"2025","journal-title":"Cancer Rep."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1517\/14656566.2010.496453","article-title":"Sorafenib: A clinical and pharmacologic review","volume":"11","author":"Iyer","year":"2010","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.3324\/haematol.2018.211615","article-title":"Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: A report of the EBMT Acute Leukemia Working Party","volume":"104","author":"Bazarbachi","year":"2019","journal-title":"Haematologica"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/bjh.16092","article-title":"Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies","volume":"187","author":"Weisberg","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s40265-017-0779-0","article-title":"Midostaurin: First Global Approval","volume":"77","author":"Kim","year":"2017","journal-title":"Drugs"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2017-05-782292","article-title":"Midostaurin approved for FLT3-mutated AML","volume":"129","author":"Levis","year":"2017","journal-title":"Blood"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41409-020-01153-1","article-title":"Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia","volume":"56","author":"Maziarz","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1182\/blood-2024-210605","article-title":"A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination with Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia","volume":"144","author":"Borate","year":"2024","journal-title":"Blood"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Molica, M., Perrone, S., Mazzone, C., Niscola, P., Cesini, L., Abruzzese, E., and de Fabritiis, P. (2021). CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin. Cancers, 13.","DOI":"10.3390\/cancers13133214"},{"key":"ref_132","first-page":"1490","article-title":"Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"11725","DOI":"10.1182\/blood-2022-165615","article-title":"Updated Analyses: Safety and Efficacy of Gemtuzumab Ozogamicin and Venetoclax in Patients with Relapsed or Refractory CD33+ Acute Myeloid Leukemia: A Phase Ib\/II Study","volume":"140","author":"Arain","year":"2020","journal-title":"Blood"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1200\/JCO.19.01406","article-title":"Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study","volume":"38","author":"Schlenk","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Godwin, C.D., Rodr\u00edguez-Arbol\u00ed, E., Othus, M., Halpern, A.B., Appelbaum, J.S., Percival, M.M., Hendrie, P.C., Oehler, V.G., Keel, S.B., and Abkowitz, J.L. (2022). Phase 1\/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms. Cancers, 14.","DOI":"10.3390\/cancers14122934"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1080\/10428194.2022.2062345","article-title":"A multi-arm phase Ib\/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed\/refractory acute myeloid leukemia","volume":"63","author":"Short","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00280-023-04578-9","article-title":"A clinical trial of zosuquidar plus gemtuzumab ozogamicin (GO) in relapsed or refractory acute myeloid leukemia (RR AML): Evidence of efficacy based on leukemic blast P-glycoprotein functional phenotype","volume":"92","author":"Marcelletti","year":"2023","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.3324\/haematol.2022.282263","article-title":"Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for FLT3- mutated acute myeloid leukemia patients\u2014Czech center experience","volume":"108","author":"Kabut","year":"2023","journal-title":"Haematologica"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1111\/bjh.19436","article-title":"Gemtuzumab ozogamicin plus midostaurin in combination with standard \u20187 + 3\u2019 induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I study","volume":"204","author":"Schliemann","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Bergel, F.S.J.A. (1954). Cyto-active amino-acid and peptide derivatives. Part I. Substituted phenylalanines. J. Chem. Soc., 2409\u20132417.","DOI":"10.1039\/jr9540002409"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1046\/j.1365-2141.1997.4763281.x","article-title":"Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia","volume":"99","author":"Parker","year":"1997","journal-title":"Br. J. Haematol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/s41409-022-01703-9","article-title":"Long-term outcomes in patients with relapsed\/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan","volume":"57","author":"Guijarro","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1007\/s00277-023-05318-y","article-title":"Analysis of long-term mortality after total body irradiation-based and melphalan-based chemotherapy conditioning for acute myeloid leukemia","volume":"102","author":"Gruber","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"66641","DOI":"10.18632\/oncotarget.18420","article-title":"Melflufen\u2014A peptidase-potentiated alkylating agent in clinical trials","volume":"8","author":"Nygren","year":"2017","journal-title":"Oncotarget"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/00001813-200309000-00006","article-title":"Antitumor activity of the alkylating oligopeptides J1 (L-melphalanyl-p-L-fluorophenylalanine ethyl ester) and P2 (L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester): Comparison with melphalan","volume":"14","author":"Gullbo","year":"2003","journal-title":"Anticancer Drugs"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.18632\/oncotarget.13856","article-title":"In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia","volume":"8","author":"Strese","year":"2017","journal-title":"Oncotarget"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2024-194582","article-title":"Efcacy of the Peptide Drug Conjugates Mel ufen and OPDC3 in Venetoclax Resistant Acute Myeloid Leukemi","volume":"144","author":"Kumari","year":"2024","journal-title":"Blood"},{"key":"ref_148","first-page":"80","article-title":"Synergistic antitumor activity of azacitidine and ubenimex on acute myeloid leukemia cells","volume":"12","author":"Chen","year":"2025","journal-title":"Aging"},{"key":"ref_149","first-page":"63","article-title":"The effect of bestatin on patients with acute and chronic leukemia and malignant lymphoma","volume":"5","author":"Arimori","year":"1980","journal-title":"Tokai J. Exp. Clin. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/BF00205548","article-title":"Immunotherapy with bestatin for acute nonlymphocytic leukemia in adults","volume":"23","author":"Ota","year":"1986","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_151","first-page":"1017","article-title":"Results of follow-up studies on prognosis after immunotherapy with bestatin in acute nonlymphocytic leukemia","volume":"13","author":"Ota","year":"1986","journal-title":"Gan Kagaku Ryoho Cancer Chemother."},{"key":"ref_152","first-page":"3047","article-title":"Immunopotentiation with Ubenimex for prevention of leukemia relapse after allogeneic BMT. The Study Group of Ubenimex for BMT","volume":"24","author":"Hiraoka","year":"1992","journal-title":"Transplant. Proc."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1756-8722-4-46","article-title":"A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"4","author":"Wei","year":"2011","journal-title":"J. Hematol. Oncol."},{"key":"ref_154","first-page":"238","article-title":"Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation","volume":"71","author":"Saito","year":"2000","journal-title":"Int. J. Hematol."},{"key":"ref_155","first-page":"1113","article-title":"Chemotherapy with ubenimex corresponding to patient age and organ disorder for 18 cases of acute myelogeneous leukemia in elderly patients--effects, complications and long-term survival","volume":"30","author":"Hirayama","year":"2003","journal-title":"Gan Kagaku Ryoho Cancer Chemother."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1021\/acs.jmedchem.7b00782","article-title":"Design of Aminopeptidase N Inhibitors as Anti-cancer Agents","volume":"61","author":"Amin","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejmech.2017.11.074","article-title":"Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy","volume":"143","author":"Jiang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Cao, J., Zhao, W., Zhao, C., Liu, Q., Li, S., Zhang, G., Chou, C.J., and Zhang, Y. (2020). Development of a Bestatin-SAHA Hybrid with Dual Inhibitory Activity against APN and HDAC. Molecules, 25.","DOI":"10.3390\/molecules25214991"},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Farsa, O., Ballayov\u00e1, V., \u017d\u00e1\u010dkov\u00e1, R., Kollar, P., Kauerov\u00e1, T., and Zub\u00e1\u010d, P. (2022). Aminopeptidase N Inhibitors as Pointers for Overcoming Antitumor Treatment Resistance. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23179813"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1200\/JCO.2009.27.6295","article-title":"Phase I\/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia","volume":"28","author":"Morgan","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S1470-2045(13)70037-8","article-title":"Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): A randomised open-label phase 2 study","volume":"14","author":"Cortes","year":"2013","journal-title":"Lancet. Oncol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/bjh.13829","article-title":"Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS","volume":"172","author":"Mawad","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1517\/13543784.2014.864276","article-title":"Tosedostat for the treatment of relapsed and refractory acute myeloid leukemia","volume":"23","author":"DiNardo","year":"2014","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Janssen, J., L\u00f6wenberg, B., Manz, M., Bargetzi, M., Biemond, B., von dem Borne, P., Breems, D., Brouwer, R., Chalandon, Y., and Deeren, D. (2021). Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. Cancers, 13.","DOI":"10.3390\/cancers13040672"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/bjh.17501","article-title":"A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: Results of the LI-1 trial","volume":"194","author":"Dennis","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"115752","DOI":"10.1016\/j.ejmech.2023.115752","article-title":"Design, synthesis, and biological evaluation of novel HDAC\/CD13 dual inhibitors for the treatment of cancer","volume":"260","author":"Jia","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"6732","DOI":"10.1158\/1078-0432.CCR-09-0842","article-title":"A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia","volume":"15","author":"Perl","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s10637-018-0585-x","article-title":"Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition","volume":"36","author":"Kasner","year":"2018","journal-title":"Investig. New Drugs"},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Palmisiano, N., Jeschke, G., Wilde, L., Alpdogan, O., Carabasi, M., Filicko-O\u2019Hara, J., Grosso, D., Klumpp, T., Martinez, U., and Wagner, J. (2023). A Phase I Trial of Sirolimus with \u201c7&3\u201d Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia. Cancers, 15.","DOI":"10.3390\/cancers15215129"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2141.2011.08940.x","article-title":"Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: Results of a phase II GIMEMA study (AML-1107)","volume":"156","author":"Amadori","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/leu.2013.17","article-title":"A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse","volume":"27","author":"Park","year":"2013","journal-title":"Leukemia"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"52269","DOI":"10.18632\/oncotarget.13699","article-title":"The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed\/refractory acute myeloid leukemia: A phase Ib\/II study","volume":"8","author":"Tan","year":"2017","journal-title":"Oncotarget"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.3324\/haematol.2018.189514","article-title":"Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: Experience from the UK NCRI AML17 trial","volume":"103","author":"Burnett","year":"2018","journal-title":"Haematologica"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.3324\/haematol.2018.200485","article-title":"Improving consolidation therapy in acute myeloid leukemia\u2014A tough nut to crack","volume":"103","author":"Schlenk","year":"2018","journal-title":"Haematologica"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/BF00435839","article-title":"Treatment of relapsed and refractory acute leukaemia with high-dose cytosine arabinoside and etoposide","volume":"23","author":"Gore","year":"1989","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000354820","article-title":"The combination of fludarabine, cytarabine and etoposide is an active and well-tolerated regimen in relapsed\/refractory acute myeloid leukemia","volume":"131","author":"Aldoss","year":"2014","journal-title":"Acta Haematol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1182\/blood-2018-99-113036","article-title":"Mitoxantrone, Etoposide and Cytarabine (MEC) Can Induce Deep Complete Remission and Is an Effective Bridge Therapy to Allotransplantation (SCT) in Refractory\/Relapsed Acute Myeloid Leukemia (AML) Patients","volume":"132","author":"Marconi","year":"2018","journal-title":"Blood"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1038\/leu.2017.165","article-title":"Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed\/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: A phase 1\/2 study","volume":"31","author":"Halpern","year":"2017","journal-title":"Leukemia"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1159\/000503056","article-title":"Etoposide Combined with FLAG Salvage Therapy Is Effective in Multiple Relapsed\/Refractory Acute Myeloid leukemia","volume":"143","author":"Westhus","year":"2020","journal-title":"Acta Haematol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1182\/blood-2023-184355","article-title":"Combination of Decitabine and Etoposide Is Highly Effective in Treating p53-Mutated MDS\/AML Via Activating Notch Signaling","volume":"142","author":"Ma","year":"2023","journal-title":"Blood"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-025-01228-6","article-title":"Decitabine with etoposide is effective in TP53 mutated myeloid tumors via overcoming differentiation block","volume":"15","author":"Ma","year":"2025","journal-title":"Blood Cancer J."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1182\/blood-2010-09-310862","article-title":"Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias","volume":"117","author":"Karp","year":"2011","journal-title":"Blood"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1158\/1078-0432.CCR-12-2926","article-title":"A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2","volume":"19","author":"Holkova","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.1158\/1078-0432.CCR-07-0381","article-title":"Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: A phase II trial in adults with poor-risk acute myelogenous leukemia","volume":"13","author":"Karp","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.leukres.2009.11.007","article-title":"Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia","volume":"34","author":"Karp","year":"2010","journal-title":"Leuk. Res."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.3324\/haematol.2012.062539","article-title":"Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia","volume":"97","author":"Karp","year":"2012","journal-title":"Haematologica"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.3324\/haematol.2015.125849","article-title":"Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine\/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia","volume":"100","author":"Zeidner","year":"2015","journal-title":"Haematologica"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.leukres.2018.08.005","article-title":"Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML)","volume":"72","author":"Zeidner","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"4258","DOI":"10.1111\/cas.15458","article-title":"Phase I study of alvocidib plus cytarabine\/mitoxantrone or cytarabine\/daunorubicin for acute myeloid leukemia in Japan","volume":"113","author":"Ikezoe","year":"2022","journal-title":"Cancer Sci."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/ajh.25333","article-title":"A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease","volume":"94","author":"Litzow","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41408-021-00568-3","article-title":"A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed\/refractory acute myeloid leukemia","volume":"11","author":"Zeidner","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/hon.3159","article-title":"A phase 1b study of venetoclax and alvocidib in patients with relapsed\/refractory acute myeloid leukemia","volume":"41","author":"Jonas","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_193","first-page":"100108","article-title":"The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed\/refractory acute myeloid leukemia","volume":"2","author":"Cook","year":"2025","journal-title":"Blood"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"4936","DOI":"10.1182\/blood.V126.23.4936.4936","article-title":"The vascular disrupting agent OXi4503 in relapsed and refractory AML and MDS","volume":"126","author":"Stockton","year":"2015","journal-title":"Blood"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1111\/bjh.16629","article-title":"Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes","volume":"189","author":"Cogle","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/bloodadvances.2018016121","article-title":"Hypomethylating agents in relapsed and refractory AML: Outcomes and their predictors in a large international patient cohort","volume":"2","author":"Stahl","year":"2018","journal-title":"Blood Adv."},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Uckun, F.M., Cogle, C.R., Lin, T.L., Qazi, S., Trieu, V.N., Schiller, G., and Watts, J.M. (2019). A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia. Cancers, 12.","DOI":"10.3390\/cancers12010074"},{"key":"ref_198","first-page":"782","article-title":"Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine","volume":"89","author":"Gerrard","year":"2004","journal-title":"Haematologica"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.leukres.2008.09.015","article-title":"A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia","volume":"33","author":"Lancet","year":"2009","journal-title":"Leuk. Res."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1182\/blood-2010-04-277269","article-title":"Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: A randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999","volume":"116","author":"Cripe","year":"2010","journal-title":"Blood"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00280-024-04656-6","article-title":"Continuous 72-h infusion of zosuquidar with chemotherapy in patients with newly diagnosed acute myeloid leukemia stratified for leukemic blast P-glycoprotein phenotype","volume":"93","author":"Marcelletti","year":"2024","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2004-05-1693","article-title":"A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia","volume":"105","author":"Byrd","year":"2005","journal-title":"Blood"},{"key":"ref_203","first-page":"2581","article-title":"Safety and Clinical Activity of Combined Romidepsin and Azacitidine Therapy in High Risk Acute Myeloid Leukemia: Preliminary Results of the Romaza Trial","volume":"130","author":"Craddock","year":"2017","journal-title":"Blood"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/bjh.17823","article-title":"Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy","volume":"196","author":"Loke","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1002\/cncr.21589","article-title":"Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia","volume":"104","author":"Bug","year":"2005","journal-title":"Cancer"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1182\/blood-2003-12-4333","article-title":"Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid","volume":"104","author":"Kuendgen","year":"2004","journal-title":"Blood"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00277-005-0026-8","article-title":"Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia","volume":"84","author":"Kuendgen","year":"2005","journal-title":"Ann. Hematol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cncr.21552","article-title":"The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia","volume":"106","author":"Kuendgen","year":"2006","journal-title":"Cancer"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1182\/blood-2006-03-009142","article-title":"Phase 1\/2 study of the combination of 5-aza-2\u2032-deoxycytidine with valproic acid in patients with leukemia","volume":"108","author":"Kantarjian","year":"2006","journal-title":"Blood"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1200\/JCO.2006.09.4169","article-title":"Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia","volume":"25","author":"Blum","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/cncr.29085","article-title":"Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia","volume":"121","author":"Issa","year":"2015","journal-title":"Cancer"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.leukres.2011.02.021","article-title":"Hematologic improvement and response in elderly AML\/RAEB patients treated with valproic acid and low-dose Ara-C","volume":"35","author":"Corsetti","year":"2011","journal-title":"Leuk. Res."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1182\/blood-2007-03-078576","article-title":"Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome","volume":"110","author":"Soriano","year":"2007","journal-title":"Blood"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"34","DOI":"10.18632\/oncotarget.106","article-title":"Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome","volume":"1","author":"Raffoux","year":"2010","journal-title":"Oncotarget"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.leukres.2008.10.005","article-title":"A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid","volume":"33","author":"Ryningen","year":"2009","journal-title":"Leuk. Res."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1038\/bcj.2011.2","article-title":"Specific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemia","volume":"1","author":"Skavland","year":"2011","journal-title":"Blood Cancer J."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1868-7083-5-13","article-title":"The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia","volume":"5","author":"Fredly","year":"2013","journal-title":"Clin. Epigenetics"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.19.01053","article-title":"Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 \u00d7 2, Phase II Trial","volume":"38","author":"Grishina","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.3324\/haematol.2022.282258","article-title":"Activity of decitabine combined with all-trans retinoic acid in oligoblastic acute myeloid leukemia: Results from a randomized 2x2 phase II trial (DECIDER)","volume":"108","author":"Rummelt","year":"2023","journal-title":"Haematologica"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1182\/blood-2013-12-546283","article-title":"Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients","volume":"123","author":"Tassara","year":"2014","journal-title":"Blood"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"6578","DOI":"10.1200\/JCO.2025.43.16_suppl.6578","article-title":"Maintenance therapy with azacitidine and valproic acid after allogeneic stem cell transplant in patients with high-risk myelodysplastic syndrome and acute myelogenous leukemia","volume":"43","author":"Whitcomb","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0145-2126(00)00162-4","article-title":"Interaction of cytosine arabinoside and lovastatin in human leukemia cells","volume":"25","author":"Holstein","year":"2001","journal-title":"Leuk. Res."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1182\/blood-2006-08-044446","article-title":"Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: A phase 1 study","volume":"109","author":"Kornblau","year":"2007","journal-title":"Blood"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.leukres.2018.01.021","article-title":"Report of the relapsed\/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML)","volume":"67","author":"Advani","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.3109\/10428194.2013.777836","article-title":"Cyclosporine modulation of multidrug resistance in combination with pravastatin, mitoxantrone and etoposide for adult patients with relapsed\/refractory acute myeloid leukemia: A phase 1\/2 study","volume":"54","author":"Chen","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"100036","DOI":"10.1016\/j.bneo.2024.100036","article-title":"A phase 1 study adding pitavastatin to venetoclax therapy in AML and CLL\/SLL: A mechanism-based drug repurposing strategy","volume":"1","author":"Brem","year":"2024","journal-title":"Blood Neoplasia"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4103\/jrpp.JRPP_17_37","article-title":"Missing the Benefit of Metformin in Acute Myeloid Leukemia: A Problem of Contrast?","volume":"6","author":"Ceacareanu","year":"2017","journal-title":"J. Res. Pharm. Pract."},{"key":"ref_228","doi-asserted-by":"crossref","unstructured":"Tseng, C.H. (2020). Metformin Use and Leukemia Risk in Patients With Type 2 Diabetes Mellitus. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.541090"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF00170778","article-title":"Phase I-II trial of acivicin in adult acute leukemia","volume":"6","author":"Powell","year":"1988","journal-title":"Investig. New Drugs"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","article-title":"TOR signaling in growth and metabolism","volume":"124","author":"Wullschleger","year":"2006","journal-title":"Cell"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2004-06-2494","article-title":"Antileukemic activity of rapamycin in acute myeloid leukemia","volume":"105","author":"Demur","year":"2005","journal-title":"Blood"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1182\/blood.V104.11.2544.2544","article-title":"Targeting of mTOR in AML Is Associated with Decreased Growth of Leukemic Cells and Downregulation of VEGF","volume":"104","author":"Boehm","year":"2004","journal-title":"Blood"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/CAD.0b013e32832e89b4","article-title":"Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinozide cytarabine","volume":"20","author":"Janus","year":"2009","journal-title":"Anticancer Drugs"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"329061","DOI":"10.1155\/2012\/329061","article-title":"Inhibition of Mammalian target of rapamycin in human acute myeloid leukemia cells has diverse effects that depend on the environmental in vitro stress","volume":"2012","author":"Ryningen","year":"2012","journal-title":"Bone Marrow Res."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.ejim.2009.09.007","article-title":"Evaluation of in vivo antineoplastic effects of rapamycin in patients with chemotherapy-refractory AML","volume":"20","author":"Boehm","year":"2009","journal-title":"Eur. J. Intern. Med."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1158\/1078-0432.CCR-07-4719","article-title":"Temsirolimus, an inhibitor of mammalian target of rapamycin","volume":"14","author":"Rini","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_237","first-page":"1205","article-title":"Everolimus (RAD001) and solid tumours: A 2008 summary","volume":"95","author":"Sauvin","year":"2008","journal-title":"Bull. Du Cancer"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1182\/blood-2006-06-030833","article-title":"Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML","volume":"109","author":"Zeng","year":"2007","journal-title":"Blood"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood-2004-11-4468","article-title":"mTOR regulates cell survival after etoposide treatment in primary AML cells","volume":"106","author":"Xu","year":"2005","journal-title":"Blood"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.18632\/oncotarget.762","article-title":"A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia","volume":"3","author":"Chiarini","year":"2012","journal-title":"Oncotarget"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"101169","DOI":"10.1016\/j.tranon.2021.101169","article-title":"Etoposide, an anticancer drug involved in therapy-related secondary leukemia: Enzymes at play","volume":"14","author":"Zhang","year":"2021","journal-title":"Transl. Oncol."},{"key":"ref_242","first-page":"119","article-title":"Comparative cytotoxicity of various drug combinations for human leukemic cells and normal hematopoietic precursors","volume":"47","author":"Chang","year":"1987","journal-title":"Cancer Res."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/BF00253972","article-title":"Etoposide-induced DNA cleavage in human leukemia cells","volume":"20","author":"Edwards","year":"1987","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1182\/blood.V80.5.1307.1307","article-title":"Sensitivity of fresh acute myeloid leukemia cells to etoposide: Relationship with cell growth characteristics and DNA single-strand breaks","volume":"80","author":"Chiron","year":"1992","journal-title":"Blood"},{"key":"ref_245","first-page":"S46","article-title":"Topoisomerase II activities in AML blasts and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines","volume":"10","author":"Gieseler","year":"1996","journal-title":"Leukemia"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1006\/bbrc.1998.8587","article-title":"Involvement of Bcl-2 cleavage in the acceleration of VP-16-induced U937 cell apoptosis","volume":"246","author":"Fujita","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_247","doi-asserted-by":"crossref","unstructured":"Bruni, E., Reichle, A., Scimeca, M., Bonanno, E., and Ghibelli, L. (2018). Lowering Etoposide Doses Shifts Cell Demise From Caspase-Dependent to Differentiation and Caspase-3-Independent Apoptosis via DNA Damage Response, Inducing AML Culture Extinction. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.01307"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/00000421-198410000-00015","article-title":"A phase II trial of VP 16-213 in adults with refractory acute myeloid leukemia. An Eastern Cooperative Oncology Group study","volume":"7","author":"Bennett","year":"1984","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/1097-0142(19910101)67:1+<281::AID-CNCR2820671312>3.0.CO;2-H","article-title":"Etoposide in acute leukemia. Past experience and future perspectives","volume":"67","author":"Ho","year":"1991","journal-title":"Cancer"},{"key":"ref_250","doi-asserted-by":"crossref","unstructured":"Joshi, H., Tuli, H.S., Ranjan, A., Chauhan, A., Haque, S., Ramniwas, S., Bhatia, G.K., and Kandari, D. (2023). The Pharmacological Implications of Flavopiridol: An Updated Overview. Molecules, 28.","DOI":"10.3390\/molecules28227530"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1074\/jbc.M304546200","article-title":"Flavopiridol inhibits NF-kappaB activation induced by various carcinogens and inflammatory agents through inhibition of IkappaBalpha kinase and p65 phosphorylation: Abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9","volume":"279","author":"Takada","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1182\/blood.V91.2.458","article-title":"Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol","volume":"91","author":"Parker","year":"1998","journal-title":"Blood"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/sj.cdd.4400868","article-title":"The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway","volume":"8","author":"Decker","year":"2001","journal-title":"Cell Death Differ."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1006\/bcmd.2001.0428","article-title":"Flavopiridol induces apoptosis and caspase-3 activation of a newly characterized Burkitt\u2019s lymphoma cell line containing mutant p53 genes","volume":"27","author":"Rapoport","year":"2001","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_255","first-page":"253","article-title":"The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1\/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells","volume":"1","author":"Rosato","year":"2002","journal-title":"Mol. Cancer Ther."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0145-2126(02)00265-5","article-title":"Flavonoid effects on normal and leukemic cells","volume":"27","author":"Liesveld","year":"2003","journal-title":"Leuk. Res."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"7062","DOI":"10.1200\/jco.2015.33.15_suppl.7062","article-title":"An alvocidib-containing regimen is highly effective in AML patients through a mechanism dependent on MCL1 expression and function","volume":"33","author":"Smith","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"8403","DOI":"10.1158\/1078-0432.CCR-05-1201","article-title":"Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias","volume":"11","author":"Karp","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3324\/haematol.2009.017103","article-title":"Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias","volume":"95","author":"Blum","year":"2010","journal-title":"Haematologica"},{"key":"ref_260","first-page":"127","article-title":"Flavopiridol disrupts STAT-3\/DNA binding and down-regulates the downstream antiapoptotic protein MCL-1 in vivo in leukemic cells from flavopiridol-treated AML patients","volume":"43","author":"Lee","year":"2002","journal-title":"Proc. Am. Assoc. Cancer Res."},{"key":"ref_261","first-page":"307","article-title":"Timed sequential therapy of acute leukemia with flavopiridol: In vitro model for a phase I clinical trial","volume":"9","author":"Karp","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.3109\/10428194.2011.591012","article-title":"Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia","volume":"52","author":"Nelson","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"ref_263","doi-asserted-by":"crossref","unstructured":"Sorf, A., Sucha, S., Morell, A., Novotna, E., Staud, F., Zavrelova, A., Visek, B., Wsol, V., and Ceckova, M. (2020). Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4\/6 Inhibitors. Cancers, 12.","DOI":"10.3390\/cancers12061596"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1182\/bloodadvances.2024014633","article-title":"A phase 1 study of the CDK9 inhibitor voruciclib in relapsed\/refractory acute myeloid leukemia and B-cell malignancies","volume":"9","author":"Davids","year":"2025","journal-title":"Blood Adv."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jconrel.2021.03.042","article-title":"Development and characterization of a novel flavopiridol formulation for treatment of acute myeloid leukemia","volume":"333","author":"Chen","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_266","first-page":"3933","article-title":"Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate","volume":"22","author":"Holwell","year":"2002","journal-title":"Anticancer Res."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1182\/blood-2009-06-230474","article-title":"Leukemia regression by vascular disruption and antiangiogenic therapy","volume":"116","author":"Madlambayan","year":"2010","journal-title":"Blood"},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1038\/leu.2012.48","article-title":"Serial monitoring of human systemic and xenograft models of leukemia using a novel vascular disrupting agent","volume":"26","author":"Benezra","year":"2012","journal-title":"Leukemia"},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ejmech.2017.06.047","article-title":"Natural alkaloids as P-gp inhibitors for multidrug resistance reversal in cancer","volume":"138","author":"Joshi","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_270","doi-asserted-by":"crossref","unstructured":"Labbozzetta, M., Poma, P., and Notarbartolo, M. (2023). Natural Inhibitors of P-glycoprotein in Acute Myeloid Leukemia. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24044140"},{"key":"ref_271","doi-asserted-by":"crossref","unstructured":"Tang, R., Faussat, A.M., Perrot, J.Y., Marjanovic, Z., Cohen, S., Storme, T., Morjani, H., Legrand, O., and Marie, J.P. (2008). Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML). BMC Cancer, 8.","DOI":"10.1186\/1471-2407-8-51"},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.leukres.2008.09.020","article-title":"Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia","volume":"33","author":"Marcelletti","year":"2009","journal-title":"Leuk. Res."},{"key":"ref_273","first-page":"3710","article-title":"A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies","volume":"8","author":"Rubin","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1158\/1078-0432.CCR-03-0644","article-title":"A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy","volume":"10","author":"Sandler","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ja.2011.35","article-title":"Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): A natural product recently approved for cutaneous T-cell lymphoma","volume":"64","author":"VanderMolen","year":"2011","journal-title":"J. Antibiot."},{"key":"ref_276","doi-asserted-by":"crossref","unstructured":"San Jos\u00e9-En\u00e9riz, E., Gimenez-Camino, N., Agirre, X., and Prosper, F. (2019). HDAC Inhibitors in Acute Myeloid Leukemia. Cancers, 11.","DOI":"10.3390\/cancers11111794"},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1182\/blood.2024027997","article-title":"Nanoromidepsin, a Polymer Nanoparticle of the HDAC Inhibitor, Improves Safety and Efficacy in Models of T-cell Lymphoma","volume":"146","author":"Pal","year":"2025","journal-title":"Blood"},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jsps.2022.12.001","article-title":"A comprehensive review on pharmacological applications and drug-induced toxicity of valproic acid","volume":"31","author":"Safdar","year":"2023","journal-title":"Saudi Pharm. J."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ctrv.2007.11.003","article-title":"Valproic acid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumors","volume":"34","author":"Candelaria","year":"2008","journal-title":"Cancer Treat. Rev."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/cncr.22891","article-title":"Valproic acid for the treatment of myeloid malignancies","volume":"110","author":"Kuendgen","year":"2007","journal-title":"Cancer"},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1868-7083-5-12","article-title":"Histone deacetylase inhibition in the treatment of acute myeloid leukemia: The effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents","volume":"5","author":"Fredly","year":"2013","journal-title":"Clin. Epigenet."},{"key":"ref_282","doi-asserted-by":"crossref","unstructured":"Kawakatsu, R., Tadagaki, K., Yamasaki, K., Kuwahara, Y., and Yoshida, T. (2025). Valproic Acid Enhances Venetoclax Efficacy in Targeting Acute Myeloid Leukemia. Diseases, 13.","DOI":"10.3390\/diseases13010010"},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1182\/blood-2013-03-488114","article-title":"Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors","volume":"123","author":"Bots","year":"2014","journal-title":"Blood"},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3324\/haematol.2013.093278","article-title":"The gene signature in CCAAT-enhancer-binding protein \u03b1 dysfunctional acute myeloid leukemia predicts responsiveness to histone deacetylase inhibitors","volume":"99","author":"Liss","year":"2014","journal-title":"Haematologica"},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"e006857","DOI":"10.1136\/jitc-2023-006857","article-title":"Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia","volume":"11","author":"Wen","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_286","doi-asserted-by":"crossref","unstructured":"Gr\u00f8nnings\u00e6ter, I.S., Fredly, H.K., Gjertsen, B.T., Hatfield, K.J., and Bruserud, \u00d8. (2019). Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy. Cells, 8.","DOI":"10.3390\/cells8101229"},{"key":"ref_287","unstructured":"Sizar, O., Khare, S., Patel, P., and Talati, R. (2025). Statin Medications. StatPearls, StatPearls Publishing LLC."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000039755","article-title":"Increased sensitivity of myeloid leukemia cell lines: Potential of lovastatin as bone-marrow-purging agent","volume":"104","author":"Scheffold","year":"2000","journal-title":"Acta Haematol."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/sj.leu.2402476","article-title":"HMG-CoA reductase inhibitors and the malignant cell: The statin family of drugs as triggers of tumor-specific apoptosis","volume":"16","author":"Wong","year":"2002","journal-title":"Leukemia"},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0145-2126(02)00085-1","article-title":"Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression","volume":"27","author":"Stirewalt","year":"2003","journal-title":"Leuk. Res."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1182\/blood.V93.4.1308","article-title":"Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach","volume":"93","author":"Dimitroulakos","year":"1999","journal-title":"Blood"},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"6461","DOI":"10.1158\/0008-5472.CAN-04-0866","article-title":"Blocking the Raf\/MEK\/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis","volume":"64","author":"Wu","year":"2004","journal-title":"Cancer Res."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1080\/10428190701760011","article-title":"Statins induce lethal effects in acute myeloblastic leukemia cells within 72 hours","volume":"49","author":"Burke","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/sj.leu.2402196","article-title":"Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells","volume":"15","author":"Xia","year":"2001","journal-title":"Leukemia"},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00277-008-0633-2","article-title":"Variability in responsiveness to lovastatin of the primitive CD34+ AML subfraction compared to normal CD34+ cells","volume":"88","author":"Kuipers","year":"2009","journal-title":"Ann. Hematol."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"eaaq1240","DOI":"10.1126\/scitranslmed.aaq1240","article-title":"Statins enhance efficacy of venetoclax in blood cancers","volume":"10","author":"Lee","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/ajh.23981","article-title":"Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"90","author":"Shadman","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"e412s","DOI":"10.6061\/clinics\/2018\/e412s","article-title":"Metformin and blood cancers","volume":"73","author":"Pericole","year":"2018","journal-title":"Clinics"},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1182\/blood-2010-02-269837","article-title":"The LKB1\/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ccr.2011.10.015","article-title":"Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia","volume":"20","author":"Sriskanthadevan","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jphs.2019.10.003","article-title":"Metformin inhibits cell proliferation in SKM-1 cells via AMPK-mediated cell cycle arrest","volume":"141","author":"Zhou","year":"2019","journal-title":"J. Pharmacol. Sci."},{"key":"ref_302","doi-asserted-by":"crossref","unstructured":"Liu, L., Patnana, P.K., Xie, X., Frank, D., Nimmagadda, S.C., Rosemann, A., Liebmann, M., Klotz, L., Opalka, B., and Khandanpour, C. (2022). High Metabolic Dependence on Oxidative Phosphorylation Drives Sensitivity to Metformin Treatment in MLL\/AF9 Acute Myeloid Leukemia. Cancers, 14.","DOI":"10.3390\/cancers14030486"},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1182\/blood-2022-167024","article-title":"Metformin Inhibits Acute Myeloid Leukemia Cells Growth through the AMPK\/mTOR Pathway and Autophagic Regulation","volume":"140","author":"Zhang","year":"2022","journal-title":"Blood"},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1182\/blood.V116.21.4351.4351","article-title":"Metformin for Therapeutic Intervention In Acute Myeloid Leukemia","volume":"116","author":"Scotland","year":"2010","journal-title":"Blood"},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.bbrc.2012.05.001","article-title":"Metformin induces differentiation in acute promyelocytic leukemia by activating the MEK\/ERK signaling pathway","volume":"422","author":"Huai","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"117276","DOI":"10.1016\/j.lfs.2020.117276","article-title":"Inhibition of mTORC1\/P70S6K pathway by Metformin synergistically sensitizes Acute Myeloid Leukemia to Ara-C","volume":"243","author":"Yuan","year":"2020","journal-title":"Life Sci."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41598-022-05470-x","article-title":"Metformin sensitizes leukemic cells to cytotoxic lymphocytes by increasing expression of intercellular adhesion molecule-1 (ICAM-1)","volume":"12","author":"Falvo","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"215582","DOI":"10.1016\/j.canlet.2022.215582","article-title":"Metformin sensitizes AML cells to chemotherapy through blocking mitochondrial transfer from stromal cells to AML cells","volume":"532","author":"You","year":"2022","journal-title":"Cancer Lett."},{"key":"ref_309","doi-asserted-by":"crossref","unstructured":"Valiulien\u0117, G., Vitkevi\u010dien\u0117, A., Skliut\u0117, G., Borutinskait\u0117, V., and Navakauskien\u0117, R. (2021). Pharmaceutical Drug Metformin and MCL1 Inhibitor S63845 Exhibit Anticancer Activity in Myeloid Leukemia Cells via Redox Remodeling. Molecules, 26.","DOI":"10.3390\/molecules26082303"},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.leukres.2016.10.004","article-title":"Synergistic cell death in FLT3-ITD positive acute myeloid leukemia by combined treatment with metformin and 6-benzylthioinosine","volume":"50","author":"Sabnis","year":"2016","journal-title":"Leuk. Res."},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.gene.2018.01.017","article-title":"Antileukemic effect of paclitaxel in combination with metformin in HL-60 cell line","volume":"647","author":"Asik","year":"2018","journal-title":"Gene"},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1002\/mc.23092","article-title":"Oxidative phosphorylation inhibition induces anticancerous changes in therapy-resistant-acute myeloid leukemia patient cells","volume":"58","author":"Janulis","year":"2019","journal-title":"Mol. Carcinog."},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"6727","DOI":"10.7150\/jca.60208","article-title":"Metformin exerts a synergistic effect with venetoclax by downregulating Mcl-1 protein in acute myeloid leukemia","volume":"12","author":"Zhou","year":"2021","journal-title":"J. Cancer"},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"101645","DOI":"10.1016\/j.xcrm.2024.101645","article-title":"Metformin synergizes with gilteritinib in treating FLT3-mutated leukemia via targeting PLK1 signaling","volume":"5","author":"Chen","year":"2024","journal-title":"Cell Rep. Med."},{"key":"ref_315","doi-asserted-by":"crossref","unstructured":"Krastinaite, I., Charkavliuk, S., Navakauskiene, R., and Borutinskaite, V.V. (2024). Metformin as an Enhancer for the Treatment of Chemoresistant CD34+ Acute Myeloid Leukemia Cells. Genes, 15.","DOI":"10.3390\/genes15050648"},{"key":"ref_316","first-page":"175","article-title":"The inhibition of gamma-glutamyl transpeptidase from human pancreatic carcinoma cells by (alpha S,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125; NSC-163501)","volume":"27","author":"Allen","year":"1980","journal-title":"Res. Commun. Chem. Pathol. Pharmacol."},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/ajh.2830210308","article-title":"Determination of ectoenzyme activities in leukemic cells and in established hematopoietic cell lines","volume":"21","author":"Morell","year":"1986","journal-title":"Am. J. Hematol."},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1182\/blood.V74.5.1728.1728","article-title":"Monocytoid differentiation of freshly isolated human myeloid leukemia cells and HL-60 cells induced by the glutamine antagonist acivicin","volume":"74","author":"Nichols","year":"1989","journal-title":"Blood"},{"key":"ref_319","first-page":"1202","article-title":"Relationship of acivicin-induced monocytoid differentiation of human myeloid leukemia cells to acivicin-induced modulation of growth factor, cytokine, and protooncogene mRNA expression","volume":"51","author":"Weinberg","year":"1991","journal-title":"Cancer Res."},{"key":"ref_320","first-page":"1163","article-title":"Inhibition of gamma-glutamyl transpeptidase activity at the surface of human myeloid cells is correlated with macrophage maturation and transforming growth factor beta production","volume":"6","author":"Bauvois","year":"1995","journal-title":"Cell Growth Differ."},{"key":"ref_321","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/978-1-4757-9613-1_31","article-title":"In vitro effects of gamma-glutamyltranspeptidase inhibitor acivicin on human myeloid and B lineage cells","volume":"421","author":"Bauvois","year":"1997","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1096\/fasebj.13.1.69","article-title":"Hydrogen peroxide produced during gamma-glutamyl transpeptidase activity is involved in prevention of apoptosis and maintainance of proliferation in U937 cells","volume":"13","author":"Paolicchi","year":"1999","journal-title":"FASEB J."},{"key":"ref_323","first-page":"69","article-title":"Enzymes transducing extracellular signals in acute myeloid human leukemias","volume":"123","author":"Losa","year":"1993","journal-title":"Schweiz. Med. Wochenschr."},{"key":"ref_324","first-page":"53","article-title":"Activities of enzyme transducing extracellular signals--gamma glutamyltransferase and enzymes metabolizing glutathione in acute lymphoblastic and myeloid human leukemias","volume":"42","author":"Rzymowska","year":"1995","journal-title":"Neoplasma"},{"key":"ref_325","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0145-2126(94)00158-7","article-title":"Biochemical effect of three different inhibitors of purine\/pyrimidine metabolism on differentiation in HL60 cells","volume":"19","author":"Ahmed","year":"1995","journal-title":"Leuk. Res."},{"key":"ref_326","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0014-5793(01)03057-5","article-title":"Reanalysis of the involvement of gamma-glutamyl transpeptidase in the cell activation process","volume":"508","author":"Antczak","year":"2001","journal-title":"FEBS Lett."},{"key":"ref_327","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1200\/JCO.1984.2.9.1064","article-title":"Acivicin: A new glutamine antagonist in clinical trials","volume":"2","author":"Alonso","year":"1984","journal-title":"J. Clin. Oncol."},{"key":"ref_328","first-page":"2763","article-title":"A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies","volume":"4","author":"Hidalgo","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"ref_329","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0168-3659(01)00327-3","article-title":"Targeting of acivicin prodrugs as antibody conjugates","volume":"74","author":"Antczak","year":"2001","journal-title":"J. Control. Release"},{"key":"ref_330","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1016\/S0968-0896(01)00145-6","article-title":"A new acivicin prodrug designed for tumor-targeted delivery","volume":"9","author":"Antczak","year":"2001","journal-title":"Bioorg. Med. Chem."},{"key":"ref_331","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.canlet.2006.01.001","article-title":"Gallic acid inhibits ribonucleotide reductase and cyclooxygenases in human HL-60 promyelocytic leukemia cells","volume":"245","author":"Madlener","year":"2007","journal-title":"Cancer Lett."},{"key":"ref_332","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1007\/s10528-023-10582-8","article-title":"The Effects of Resveratrol, Gallic Acid, and Piperine on the Expression of miR-17, miR-92b, miR-181a, miR-222, BAX, BCL-2, MCL-1, WT1, c-Kit, and CEBPA in Human Acute Myeloid Leukemia Cells and Their Roles in Apoptosis","volume":"62","author":"Moayedi","year":"2024","journal-title":"Biochem. Genet."},{"key":"ref_333","doi-asserted-by":"crossref","unstructured":"Xiang, W., Sng, C., Lam, Y.H., Kok, Z.H., Linn, Y.C., Neo, S.Y., Siew, Y.Y., Singh, D., Koh, H.L., and Chuah, C. (2024). Gallic Acid Enhances the Efficacy of BCR::ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia through Inhibition of Mitochondrial Respiration and Modulation of Oncogenic Signaling Pathways. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25147958"},{"key":"ref_334","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.tiv.2011.12.018","article-title":"Anti-leukemic effects of gallic acid on human leukemia K562 cells: Downregulation of COX-2, inhibition of BCR\/ABL kinase and NF-\u03baB inactivation","volume":"26","author":"Reddy","year":"2012","journal-title":"Toxicol. In Vitro"},{"key":"ref_335","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.biopha.2018.05.158","article-title":"Gallic acid targets acute myeloid leukemia via Akt\/mTOR-dependent mitochondrial respiration inhibition","volume":"105","author":"Gu","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_336","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/mnfr.201200167","article-title":"Gallic acid downregulates matrix metalloproteinase-2 (MMP-2) and MMP-9 in human leukemia cells with expressed Bcr\/Abl","volume":"56","author":"Chen","year":"2012","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_337","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0024-3205(96)00603-0","article-title":"Effect of (-)-epigallocatechin gallate on leukemic blast cells from patients with acute myeloblastic leukemia","volume":"60","author":"Asano","year":"1997","journal-title":"Life Sci."},{"key":"ref_338","doi-asserted-by":"crossref","unstructured":"Ly, B.T., Chi, H.T., Yamagishi, M., Kano, Y., Hara, Y., Nakano, K., Sato, Y., and Watanabe, T. (2013). Inhibition of FLT3 expression by green tea catechins in FLT3 mutated-AML cells. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0066378"},{"key":"ref_339","first-page":"1417","article-title":"Anti-proliferative and apoptosis induction activity of green tea polyphenols on human promyelocytic leukemia HL-60 cells","volume":"29","author":"Han","year":"2009","journal-title":"Anticancer Res."},{"key":"ref_340","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2141.2009.08040.x","article-title":"Epigallocatechin-3-gallate induces cell death in acute myeloid leukaemia cells and supports all-trans retinoic acid-induced neutrophil differentiation via death-associated protein kinase 2","volume":"149","author":"Britschgi","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_341","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/10428194.2017.1339881","article-title":"Green tea polyphenol EGCG causes anti-cancerous epigenetic modulations in acute promyelocytic leukemia cells","volume":"59","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_342","doi-asserted-by":"crossref","first-page":"9103","DOI":"10.1038\/s41598-021-88478-z","article-title":"(-)-Epigallocatechin-3-gallate induces apoptosis and differentiation in leukaemia by targeting reactive oxygen species and PIN1","volume":"11","author":"Shiraishi","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_343","first-page":"317","article-title":"Catechin, a green tea component, rapidly induces apoptosis of myeloid leukemic cells via modulation of reactive oxygen species production in vitro and inhibits tumor growth in vivo","volume":"90","author":"Nakazato","year":"2005","journal-title":"Haematologica"},{"key":"ref_344","first-page":"25","article-title":"Combined effect of (-)-epigallocatechin-3-gallate and all-trans retinoic acid in FLT3-mutated cell lines","volume":"13","author":"Ly","year":"2020","journal-title":"Biomed. Rep."},{"key":"ref_345","first-page":"314","article-title":"A comparative study of anti-leukemic effects of kaempferol and epigallocatechin-3-gallate (EGCG) on human leukemia HL-60 cells","volume":"11","author":"Jokar","year":"2021","journal-title":"Avicenna J. Phytomed."},{"key":"ref_346","doi-asserted-by":"crossref","unstructured":"Bae, K.H., Lai, F., Oruc, B., Osato, M., Chen, Q., and Kurisawa, M. (2022). Self-Assembled Daunorubicin\/Epigallocatechin Gallate Nanocomplex for Synergistic Reversal of Chemoresistance in Leukemia. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24010381"},{"key":"ref_347","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1186\/s12951-022-01683-4","article-title":"Bone marrow-targetable Green Tea Catechin-Based Micellar Nanocomplex for synergistic therapy of Acute myeloid leukemia","volume":"20","author":"Bae","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"ref_348","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1039\/C9BM01146C","article-title":"A two-pronged anti-leukemic agent based on a hyaluronic acid-green tea catechin conjugate for inducing targeted cell death and terminal differentiation","volume":"8","author":"Liang","year":"2019","journal-title":"Biomater. Sci."},{"key":"ref_349","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1182\/blood-2014-10-604975","article-title":"Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia","volume":"126","author":"Pan","year":"2015","journal-title":"Blood"},{"key":"ref_350","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s11523-017-0509-2","article-title":"The pan-Bcl2 Inhibitor AT101 Activates the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells","volume":"12","author":"Zhang","year":"2017","journal-title":"Target. Oncol."},{"key":"ref_351","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.canlet.2019.07.003","article-title":"Synthetic lethality of combined AT-101 with idarubicin in acute myeloid leukemia via blockade of DNA repair and activation of intrinsic apoptotic pathway","volume":"461","author":"Yang","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_352","doi-asserted-by":"crossref","first-page":"444","DOI":"10.4252\/wjsc.v16.i4.444","article-title":"Gossypol acetic acid regulates leukemia stem cells by degrading LRPPRC via inhibiting IL-6\/JAK1\/STAT3 signaling or resulting mitochondrial dysfunction","volume":"16","author":"Ai","year":"2024","journal-title":"World J. Stem Cells"},{"key":"ref_353","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1126\/science.275.5297.218","article-title":"Cancer chemopreventive activity of resveratrol, a natural product derived from grapes","volume":"275","author":"Jang","year":"1997","journal-title":"Science"},{"key":"ref_354","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3835(99)00039-7","article-title":"Resveratrol, an antioxidant present in red wine, induces apoptosis in human promyelocytic leukemia (HL-60) cells","volume":"140","author":"Surh","year":"1999","journal-title":"Cancer Lett."},{"key":"ref_355","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0304-3835(00)00658-3","article-title":"Chemopreventive agent resveratrol, a natural product derived from grapes, reversibly inhibits progression through S and G2 phases of the cell cycle in U937 cells","volume":"163","author":"Park","year":"2001","journal-title":"Cancer Lett."},{"key":"ref_356","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/carcin\/23.8.1327","article-title":"Resveratrol inhibits the growth and induces the apoptosis of both normal and leukemic hematopoietic cells","volume":"23","author":"Garnier","year":"2002","journal-title":"Carcinogenesis"},{"key":"ref_357","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1124\/mol.112.079624","article-title":"Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway","volume":"82","author":"Yaseen","year":"2012","journal-title":"Mol. Pharmacol."},{"key":"ref_358","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1080\/10428190290021669","article-title":"Anti-leukemia effect of resveratrol","volume":"43","author":"Tsan","year":"2002","journal-title":"Leuk. Lymphoma"},{"key":"ref_359","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1182\/blood-2002-11-3550","article-title":"Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells","volume":"102","author":"Estrov","year":"2003","journal-title":"Blood"},{"key":"ref_360","first-page":"60","article-title":"The cytotoxic effect of curcumin, demethoxycurcumin and bisdemethoxycurcumin purified from Turmeric powder on leukemic cell lines","volume":"39","author":"Anuchapreedr","year":"2006","journal-title":"Bull. Chisng Mti Assoc. Mcd Sci."},{"key":"ref_361","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00109-014-1198-2","article-title":"Inactivation of FoxM1 transcription factor contributes to curcumin-induced inhibition of survival, angiogenesis, and chemosensitivity in acute myeloid leukemia cells","volume":"92","author":"Zhang","year":"2014","journal-title":"J. Mol. Med."},{"key":"ref_362","doi-asserted-by":"crossref","first-page":"968981","DOI":"10.1155\/2015\/968981","article-title":"Curcumin and its analogue induce apoptosis in leukemia cells and have additive effects with bortezomib in cellular and xenograft models","volume":"2015","author":"Nagy","year":"2015","journal-title":"BioMed Res. Int."},{"key":"ref_363","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.3892\/or.2016.4944","article-title":"Curcumin reduces the expression of survivin, leading to enhancement of arsenic trioxide-induced apoptosis in myelodysplastic syndrome and leukemia stem-like cells","volume":"36","author":"Zeng","year":"2016","journal-title":"Oncol. Rep."},{"key":"ref_364","first-page":"3055","article-title":"Anti-Vascular Endothelial Growth Factor Targeting by Curcumin and Thalidomide in Acute Myeloid Leukemia Cells","volume":"18","author":"Salemi","year":"2017","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_365","first-page":"6777","article-title":"Curcumin differentially affects cell cycle and cell death in acute and chronic myeloid leukemia cells","volume":"15","author":"Berumen","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_366","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/13880209.2019.1701042","article-title":"Curcumin inhibited the growth and invasion of human monocytic leukaemia SHI-1 cells in vivo by altering MAPK and MMP signalling","volume":"58","author":"Zhu","year":"2020","journal-title":"Pharm. Biol."},{"key":"ref_367","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.21873\/anticanres.13659","article-title":"Synergistic Antioncogenic Activity of Azacitidine and Curcumin in Myeloid Leukemia Cell Lines and Patient Samples","volume":"39","author":"Navarro","year":"2019","journal-title":"Anticancer Res."},{"key":"ref_368","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1479-5876-9-71","article-title":"Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells","volume":"9","author":"Rao","year":"2011","journal-title":"J. Transl. Med."},{"key":"ref_369","doi-asserted-by":"crossref","unstructured":"Yu, J., Peng, Y., Wu, L.C., Xie, Z., Deng, Y., Hughes, T., He, S., Mo, X., Chiu, M., and Wang, Q.E. (2013). Curcumin down-regulates DNA methyltransferase 1 and plays an anti-leukemic role in acute myeloid leukemia. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0055934"},{"key":"ref_370","doi-asserted-by":"crossref","unstructured":"Chueahongthong, F., Tima, S., Chiampanichayakul, S., Berkland, C., and Anuchapreeda, S. (2021). Co-Treatments of Edible Curcumin from Turmeric Rhizomes and Chemotherapeutic Drugs on Cytotoxicity and FLT3 Protein Expression in Leukemic Stem Cells. Molecules, 26.","DOI":"10.21203\/rs.3.rs-467881\/v1"},{"key":"ref_371","first-page":"1303","article-title":"Curcumin induces apoptosis and suppresses invasion through MAPK and MMP signaling in human monocytic leukemia SHI-1 cells","volume":"54","author":"Zhu","year":"2016","journal-title":"Pharm. Biol."},{"key":"ref_372","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3892\/or.2021.7962","article-title":"Curcumin promotes cell cycle arrest and apoptosis of acute myeloid leukemia cells by inactivating AKT","volume":"45","author":"Zhou","year":"2021","journal-title":"Oncol. Rep."},{"key":"ref_373","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/s41374-021-00640-3","article-title":"Curcumin attenuates Adriamycin-resistance of acute myeloid leukemia by inhibiting the lncRNA HOTAIR\/miR-20a-5p\/WT1 axis","volume":"101","author":"Liu","year":"2021","journal-title":"Lab. Investig."},{"key":"ref_374","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/jcb.21528","article-title":"Differential apoptotic effect of wogonin and nor-wogonin via stimulation of ROS production in human leukemia cells","volume":"103","author":"Chow","year":"2008","journal-title":"J. Cell. Biochem."},{"key":"ref_375","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.phymed.2009.06.005","article-title":"Wogonin, an active compound in Scutellaria baicalensis, induces apoptosis and reduces telomerase activity in the HL-60 leukemia cells","volume":"17","author":"Huang","year":"2010","journal-title":"Phytomedicine"},{"key":"ref_376","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.3892\/or.2015.3896","article-title":"Wogonin induces apoptosis and endoplasmic reticulum stress in HL-60 leukemia cells through inhibition of the PI3K-AKT signaling pathway","volume":"33","author":"Hu","year":"2015","journal-title":"Oncol. Rep."},{"key":"ref_377","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1002\/ctm2.154","article-title":"Natural HDAC-1\/8 inhibitor baicalein exerts therapeutic effect in CBF-AML","volume":"10","author":"Yu","year":"2020","journal-title":"Clin. Transl. Med."},{"key":"ref_378","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2174\/1570180820666230217092156","article-title":"Baicalein Promotes Acute Myeloid Leukemia Cell Autophagy via miR-424 and the PTEN\/PI3K\/AKT\/mTOR Pathway","volume":"21","author":"Li","year":"2024","journal-title":"Lett. Drug Des. Discov."},{"key":"ref_379","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/S0959-8049(99)00168-9","article-title":"Induction of apoptosis by apigenin and related flavonoids through cytochrome c release and activation of caspase-9 and caspase-3 in leukaemia HL-60 cells","volume":"35","author":"Wang","year":"1999","journal-title":"Eur. J. Cancer"},{"key":"ref_380","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.bcp.2006.06.010","article-title":"Apigenin-induced-apoptosis is mediated by the activation of PKCdelta and caspases in leukemia cells","volume":"72","author":"Vargo","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"ref_381","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1038\/cddis.2009.18","article-title":"Cytotoxicity of apigenin on leukemia cell lines: Implications for prevention and therapy","volume":"1","author":"Fuhler","year":"2010","journal-title":"Cell Death Dis."},{"key":"ref_382","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1038\/cddis.2010.41","article-title":"Apigenin-induced apoptosis of leukemia cells is mediated by a bimodal and differentially regulated residue-specific phosphorylation of heat-shock protein-27","volume":"1","author":"Voss","year":"2010","journal-title":"Cell Death Dis."},{"key":"ref_383","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1158\/1535-7163.MCT-11-0343","article-title":"Apigenin induces apoptosis in human leukemia cells and exhibits anti-leukemic activity in vivo","volume":"11","author":"Budhraja","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_384","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.2174\/18715206113139990303","article-title":"Differential effects of polyphenols on proliferation and apoptosis in human myeloid and lymphoid leukemia cell lines","volume":"13","author":"Mahbub","year":"2013","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"ref_385","doi-asserted-by":"crossref","first-page":"15043","DOI":"10.1038\/cddiscovery.2015.43","article-title":"Polyphenols act synergistically with doxorubicin and etoposide in leukaemia cell lines","volume":"1","author":"Mahbub","year":"2015","journal-title":"Cell Death Discov."},{"key":"ref_386","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.18632\/oncotarget.27068","article-title":"Polyphenols enhance the activity of alkylating agents in leukaemia cell lines","volume":"10","author":"Mahbub","year":"2019","journal-title":"Oncotarget"},{"key":"ref_387","doi-asserted-by":"crossref","first-page":"8858","DOI":"10.1038\/s41598-022-11441-z","article-title":"The effect of apigenin and chemotherapy combination treatments on apoptosis-related genes and proteins in acute leukaemia cell lines","volume":"12","author":"Mahbub","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_388","doi-asserted-by":"crossref","first-page":"5679","DOI":"10.1158\/1078-0432.CCR-10-1565","article-title":"Quercetin induces tumor-selective apoptosis through downregulation of Mcl-1 and activation of Bax","volume":"16","author":"Cheng","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_389","doi-asserted-by":"crossref","first-page":"7785","DOI":"10.1007\/s11033-012-1621-0","article-title":"Quercetin-induced apoptosis of HL-60 cells by reducing PI3K\/Akt","volume":"39","author":"Yuan","year":"2012","journal-title":"Mol. Biol. Rep."},{"key":"ref_390","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00204-014-1300-0","article-title":"Quercetin induces mitochondrial-derived apoptosis via reactive oxygen species-mediated ERK activation in HL-60 leukemia cells and xenograft","volume":"89","author":"Lee","year":"2015","journal-title":"Arch. Toxicol."},{"key":"ref_391","doi-asserted-by":"crossref","unstructured":"Shi, H., Li, X.Y., Chen, Y., Zhang, X., Wu, Y., Wang, Z.X., Chen, P.H., Dai, H.Q., Feng, J., and Chatterjee, S. (2020). Quercetin Induces Apoptosis via Downregulation of Vascular Endothelial Growth Factor\/Akt Signaling Pathway in Acute Myeloid Leukemia Cells. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.534171"},{"key":"ref_392","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13148-018-0563-3","article-title":"The polyphenol quercetin induces cell death in leukemia by targeting epigenetic regulators of pro-apoptotic genes","volume":"10","author":"Alvarez","year":"2018","journal-title":"Clin. Epigenetics"},{"key":"ref_393","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1365-2141.1991.tb08082.x","article-title":"Antiproliferative activity of quercetin on normal bone marrow and leukaemic progenitors","volume":"79","author":"Larocca","year":"1991","journal-title":"Br. J. Haematol."},{"key":"ref_394","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1182\/blood.V85.12.3654.bloodjournal85123654","article-title":"Quercetin inhibits the growth of leukemic progenitors and induces the expression of transforming growth factor-beta 1 in these cells","volume":"85","author":"Larocca","year":"1995","journal-title":"Blood"},{"key":"ref_395","doi-asserted-by":"crossref","unstructured":"Sun, J., Sha, M., Zhou, J., and Huang, Y. (2025). Quercetin affects apoptosis and autophagy in pediatric acute myeloid leukaemia cells by inhibiting PI3K\/AKT signaling pathway activation through regulation of miR-224-3p\/PTEN axis. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-13709-9"},{"key":"ref_396","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1038\/s41598-018-21516-5","article-title":"Antitumor activities of Quercetin and Green Tea in xenografts of human leukemia HL60 cells","volume":"8","author":"Calgarotto","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_397","doi-asserted-by":"crossref","first-page":"26418","DOI":"10.1038\/s41598-024-78221-9","article-title":"The combination of venetoclax and quercetin exerts a cytotoxic effect on acute myeloid leukemia","volume":"14","author":"Kawakatsu","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_398","first-page":"1244","article-title":"Quercetin induces autophagy-associated death in HL-60 cells through CaMKK\u03b2\/AMPK\/mTOR signal pathway","volume":"54","author":"Xiao","year":"2022","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"ref_399","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/jcb.22044","article-title":"Kaempferol induces apoptosis in two different cell lines via Akt inactivation, Bax and SIRT3 activation, and mitochondrial dysfunction","volume":"106","author":"Marfe","year":"2009","journal-title":"J. Cell. Biochem."},{"key":"ref_400","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1016\/j.fct.2008.09.056","article-title":"Naringenin induces apoptosis through downregulation of Akt and caspase-3 activation in human leukemia THP-1 cells","volume":"46","author":"Park","year":"2008","journal-title":"Food Chem. Toxicol."},{"key":"ref_401","doi-asserted-by":"crossref","first-page":"e15826","DOI":"10.1016\/j.heliyon.2023.e15826","article-title":"Naringenin induces the cell apoptosis of acute myeloid leukemia cells by regulating the lncRNA XIST\/miR-34a\/HDAC1 signaling","volume":"9","author":"Wen","year":"2023","journal-title":"Heliyon"},{"key":"ref_402","doi-asserted-by":"crossref","first-page":"8223","DOI":"10.3892\/mmr.2015.4480","article-title":"Co-treatment of THP-1 cells with naringenin and curcumin induces cell cycle arrest and apoptosis via numerous pathways","volume":"12","author":"Shi","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"ref_403","doi-asserted-by":"crossref","first-page":"11903","DOI":"10.1007\/s13277-014-2457-0","article-title":"Nobiletin suppresses the proliferation and induces apoptosis involving MAPKs and caspase-8\/-9\/-3 signals in human acute myeloid leukemia cells","volume":"35","author":"Hsiao","year":"2014","journal-title":"Tumour Biol."},{"key":"ref_404","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3390\/ijms16010645","article-title":"Morin, a flavonoid from moraceae, induces apoptosis by induction of BAD protein in human leukemic cells","volume":"16","author":"Park","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_405","first-page":"1115","article-title":"Hispidulin induces mitochondrial apoptosis in acute myeloid leukemia cells by targeting extracellular matrix metalloproteinase inducer","volume":"8","author":"Gao","year":"2016","journal-title":"Am. J. Transl. Res."},{"key":"ref_406","first-page":"358","article-title":"Effect of Scutellarin on Proliferation of Acute Myeloid Leukemia Cells and Its Related Mechanism","volume":"31","author":"Chen","year":"2023","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"ref_407","doi-asserted-by":"crossref","first-page":"107127","DOI":"10.1016\/j.toxicon.2023.107127","article-title":"Silymarin in combination with ATRA enhances apoptosis induction in human acute promyelocytic NB4 cells","volume":"228","author":"Parsa","year":"2023","journal-title":"Toxicon"},{"key":"ref_408","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1021\/jm021109f","article-title":"Synthesis and biological evaluation of novel flavone-8-acetic acid derivatives as reversible inhibitors of aminopeptidase N\/CD13","volume":"46","author":"Bauvois","year":"2003","journal-title":"J. Med. Chem."},{"key":"ref_409","doi-asserted-by":"crossref","first-page":"19445","DOI":"10.18632\/oncotarget.6523","article-title":"The CNGRC-GG-D(KLAKLAK)2 peptide induces a caspase-independent, Ca2+-dependent death in human leukemic myeloid cells by targeting surface aminopeptidase N\/CD13","volume":"7","author":"Bouchet","year":"2016","journal-title":"Oncotarget"},{"key":"ref_410","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.bbamcr.2013.02.016","article-title":"p70S6 kinase is a target of the novel proteasome inhibitor 3,3\u2032-diamino-4\u2032-methoxyflavone during apoptosis in human myeloid tumor cells","volume":"1833","author":"Piedfer","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_411","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/CAD.0b013e328353f947","article-title":"2\u2032-Nitroflavone induces apoptosis and modulates mitogen-activated protein kinase pathways in human leukaemia cells","volume":"23","author":"Blank","year":"2012","journal-title":"Anticancer Drugs"},{"key":"ref_412","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s12272-001-1280-8","article-title":"Structurally related cytotoxic effects of flavonoids on human cancer cells in vitro","volume":"31","author":"Chang","year":"2008","journal-title":"Arch. Pharmacal Res."},{"key":"ref_413","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejphar.2010.08.020","article-title":"3,6-Dihydroxyflavone induces apoptosis in leukemia HL-60 cell via reactive oxygen species-mediated p38 MAPK\/JNK pathway","volume":"648","author":"Chang","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"ref_414","doi-asserted-by":"crossref","first-page":"49777","DOI":"10.18632\/oncotarget.10446","article-title":"A novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia","volume":"7","author":"Jeyaraju","year":"2016","journal-title":"Oncotarget"},{"key":"ref_415","first-page":"115981","article-title":"Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and\/or purine biosynthesis","volume":"220","author":"Hurrish","year":"2023","journal-title":"Res. Sq."},{"key":"ref_416","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0006-2952(01)00860-7","article-title":"Induction of apoptosis by diallyl disulfide through activation of caspase-3 in human leukemia HL-60 cells","volume":"63","author":"Kwon","year":"2002","journal-title":"Biochem. Pharmacol."},{"key":"ref_417","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1142\/S0192415X02000338","article-title":"Effects of garlic components diallyl sulfide and diallyl disulfide on arylamine N-acetyltransferase activity and 2-aminofluorene-DNA adducts in human promyelocytic leukemia cells","volume":"30","author":"Lin","year":"2002","journal-title":"Am. J. Chin. Med."},{"key":"ref_418","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1007\/s12272-001-1227-0","article-title":"Inhibition of ERK and activation of p38 are involved in diallyl disulfide induced apoptosis of leukemia HL-60 cells","volume":"31","author":"Tan","year":"2008","journal-title":"Arch. Pharmacal Res."},{"key":"ref_419","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/01635581.2013.776090","article-title":"Role of di-allyl disulfide, a garlic component in NF-\u03baB mediated transient G2-M phase arrest and apoptosis in human leukemic cell-lines","volume":"65","author":"Dasgupta","year":"2013","journal-title":"Nutr. Cancer"},{"key":"ref_420","doi-asserted-by":"crossref","first-page":"6345","DOI":"10.21873\/anticanres.14655","article-title":"Potentiation of Differentiation and Apoptosis in a Human Promyelocytic Leukemia Cell Line by Garlic Essential Oil and Its Organosulfur Compounds","volume":"40","author":"Agassi","year":"2020","journal-title":"Anticancer Res."},{"key":"ref_421","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/(SICI)1097-4644(1997)27+<106::AID-JCB17>3.0.CO;2-L","article-title":"Initial study on naturally occurring products from traditional Chinese herbs and vegetables for chemoprevention","volume":"27","author":"Zheng","year":"1997","journal-title":"J. Cell Biochem. Suppl."},{"key":"ref_422","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s10495-009-0328-8","article-title":"Cell cycle arrest in early mitosis and induction of caspase-dependent apoptosis in U937 cells by diallyltetrasulfide (Al2S4)","volume":"14","author":"Cerella","year":"2009","journal-title":"Apoptosis"},{"key":"ref_423","first-page":"3519","article-title":"Ajoene, a garlic-derived natural compound, enhances chemotherapy-induced apoptosis in human myeloid leukaemia CD34-positive resistant cells","volume":"21","author":"Ahmed","year":"2001","journal-title":"Anticancer Res."},{"key":"ref_424","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1472-8206.2004.00219.x","article-title":"Effect of ajoene, a natural antitumor small molecule, on human 20S proteasome activity in vitro and in human leukemic HL60 cells","volume":"18","author":"Xu","year":"2004","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_425","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.leukres.2003.10.008","article-title":"Ajoene (natural garlic compound): A new anti-leukaemia agent for AML therapy","volume":"28","author":"Hassan","year":"2004","journal-title":"Leuk. Res."},{"key":"ref_426","first-page":"885","article-title":"Allium compounds, dipropyl and dimethyl thiosulfinates as antiproliferative and differentiating agents of human acute myeloid leukemia cell lines","volume":"2","author":"Merhi","year":"2008","journal-title":"Biologics"},{"key":"ref_427","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s12185-010-0686-6","article-title":"C\/EBP\u03b2 and CHOP participate in tanshinone IIA-induced differentiation and apoptosis of acute promyelocytic leukemia cells in vitro","volume":"92","author":"Zhang","year":"2010","journal-title":"Int. J. Hematol."},{"key":"ref_428","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1007\/s10495-009-0407-x","article-title":"The coffee diterpene kahweol induces apoptosis in human leukemia U937 cells through down-regulation of Akt phosphorylation and activation of JNK","volume":"14","author":"Oh","year":"2009","journal-title":"Apoptosis"},{"key":"ref_429","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nchembio.935","article-title":"Adenanthin targets peroxiredoxin I and II to induce differentiation of leukemic cells","volume":"8","author":"Liu","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"ref_430","doi-asserted-by":"crossref","first-page":"127ra138","DOI":"10.1126\/scitranslmed.3003562","article-title":"Targeting of AML1-ETO in t(8;21) leukemia by oridonin generates a tumor suppressor-like protein","volume":"4","author":"Zhen","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_431","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1182\/blood-2007-05-091504","article-title":"Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5","volume":"111","author":"Carter","year":"2008","journal-title":"Blood"},{"key":"ref_432","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/CAD.0b013e3283409673","article-title":"Ursolic acid induces HL60 monocytic differentiation and upregulates C\/EBP\u03b2 expression by ERK pathway activation","volume":"22","author":"Zhang","year":"2011","journal-title":"Anticancer Drugs"},{"key":"ref_433","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0939-6411(03)00046-8","article-title":"Hyperforin a constituent of St John\u2019s wort (Hypericum perforatum L.) extract induces apoptosis by triggering activation of caspases and with hypericin synergistically exerts cytotoxicity towards human malignant cell lines","volume":"56","author":"Hostanska","year":"2003","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_434","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.cbi.2011.02.026","article-title":"Induction of apoptosis in K562 cells by dicyclohexylammonium salt of hyperforin through a mitochondrial-related pathway","volume":"190","author":"Liu","year":"2011","journal-title":"Chem.-Biol. Interact."},{"key":"ref_435","doi-asserted-by":"crossref","unstructured":"Merhi, F., Tang, R., Piedfer, M., Mathieu, J., Bombarda, I., Zaher, M., Kolb, J.P., Billard, C., and Bauvois, B. (2011). Hyperforin Inhibits Akt1 Kinase Activity and Promotes Caspase-mediated Apoptosis involving Bad and Noxa Activation in Human Myeloid Tumor Cells. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0025963"},{"key":"ref_436","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1080\/10428190701474332","article-title":"Hyperforin inhibits P-gp and BCRP activities in chronic lymphocytic leukaemia cells and myeloid cells","volume":"48","author":"Quiney","year":"2007","journal-title":"Leuk. Lymphoma"},{"key":"ref_437","doi-asserted-by":"crossref","unstructured":"Skopek, R., Palusi\u0144ska, M., Kaczor-Keller, K., Pingwara, R., Papierniak-Wygl\u0105da\u0142a, A., Schenk, T., Lewicki, S., Zelent, A., and Szyma\u0144ski, \u0141. (2023). Choosing the Right Cell Line for Acute Myeloid Leukemia (AML) Research. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065377"},{"key":"ref_438","first-page":"583","article-title":"Flavonoids in Cancer Prevention and Therapy: Chemistry, Pharmacology, Mechanisms of Action, and Perspectives for Cancer Drug Discovery","volume":"15","author":"Chabot","year":"2010","journal-title":"Altern. Complement. Ther. Cancer"},{"key":"ref_439","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.5740\/jaoacint.19-0133","article-title":"Natural Polyphenols: Chemical Classification, Definition of Classes, Subcategories, and Structures","volume":"102","author":"Singla","year":"2019","journal-title":"J. AOAC Int."},{"key":"ref_440","doi-asserted-by":"crossref","unstructured":"Carrano, R., Grande, M., Leti Maggio, E., Zucca, C., Bei, R., Palumbo, C., Focaccetti, C., Nardozi, D., Lucarini, V., and Angiolini, V. (2024). Dietary Polyphenols Effects on Focal Adhesion Plaques and Metalloproteinases in Cancer Invasiveness. Biomedicines, 12.","DOI":"10.3390\/biomedicines12030482"},{"key":"ref_441","doi-asserted-by":"crossref","unstructured":"Dias, M.C., Pinto, D., and Silva, A.M.S. (2021). Plant Flavonoids: Chemical Characteristics and Biological Activity. Molecules, 26.","DOI":"10.3390\/molecules26175377"},{"key":"ref_442","doi-asserted-by":"crossref","unstructured":"Liga, S., Paul, C., and P\u00e9ter, F. (2023). Flavonoids: Overview of Biosynthesis, Biological Activity, and Current Extraction Techniques. Plants, 12.","DOI":"10.3390\/plants12142732"},{"key":"ref_443","doi-asserted-by":"crossref","first-page":"112576","DOI":"10.1016\/j.fct.2021.112576","article-title":"Gallic acid for cancer therapy: Molecular mechanisms and boosting efficacy by nanoscopical delivery","volume":"157","author":"Ashrafizadeh","year":"2021","journal-title":"Food Chem. Toxicol."},{"key":"ref_444","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.2147\/DDDT.S202818","article-title":"In vitro and in vivo effect of hyaluronic acid modified, doxorubicin and gallic acid co-delivered lipid-polymeric hybrid nano-system for leukemia therapy","volume":"13","author":"Shao","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_445","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2174\/1871520620666200717142315","article-title":"Activation of Myosin Phosphatase by Epigallocatechin-Gallate Sensitizes THP-1 Leukemic Cells to Daunorubicin","volume":"21","author":"Kiss","year":"2021","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"ref_446","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.chembiol.2004.02.020","article-title":"Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L)","volume":"11","author":"Becattini","year":"2004","journal-title":"Chem. Biol."},{"key":"ref_447","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1021\/jm030190z","article-title":"Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte\/leukemia-2 proteins","volume":"46","author":"Kitada","year":"2003","journal-title":"J. Med. Chem."},{"key":"ref_448","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.bcp.2008.08.003","article-title":"Regulation of antiapoptotic MCL-1 function by gossypol: Mechanistic insights from in vitro reconstituted systems","volume":"76","author":"Etxebarria","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"ref_449","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09205063.2025.2554978","article-title":"Gossypol-based nanocarriers for cancer treatment: Advances and future perspectives","volume":"11","author":"Swarn","year":"2025","journal-title":"J. Biomater. Sci. Polym. Ed."},{"key":"ref_450","doi-asserted-by":"crossref","first-page":"e202402872","DOI":"10.1002\/cbdv.202402872","article-title":"Gossypol and Semisynthetic Derivatives: Chemistry, Bioactivities, and Mechanism of Actions","volume":"22","author":"Sharma","year":"2025","journal-title":"Chem. Biodivers."},{"key":"ref_451","doi-asserted-by":"crossref","unstructured":"Shaito, A., Posadino, A.M., Younes, N., Hasan, H., Halabi, S., Alhababi, D., Al-Mohannadi, A., Abdel-Rahman, W.M., Eid, A.H., and Nasrallah, G.K. (2020). Potential Adverse Effects of Resveratrol: A Literature Review. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21062084"},{"key":"ref_452","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s12032-021-01627-2","article-title":"Resveratrol triggers anti-proliferative and apoptotic effects in FLT3-ITD-positive acute myeloid leukemia cells via inhibiting ceramide catabolism enzymes","volume":"39","author":"Adan","year":"2022","journal-title":"Med. Oncol."},{"key":"ref_453","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.drudis.2010.07.005","article-title":"Resveratrol and derivatives for the prevention and treatment of cancer","volume":"15","author":"Fulda","year":"2010","journal-title":"Drug Discov. Today"},{"key":"ref_454","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.exphem.2006.05.018","article-title":"Cytotoxic and biochemical effects of 3,3\u2032,4,4\u2032,5,5\u2032-hexahydroxystilbene, a novel resveratrol analog in HL-60 human promyelocytic leukemia cells","volume":"34","author":"Horvath","year":"2006","journal-title":"Exp. Hematol."},{"key":"ref_455","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1158\/1940-6207.CAPR-11-0148","article-title":"Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamics","volume":"4","author":"Howells","year":"2011","journal-title":"Cancer Prev. Res."},{"key":"ref_456","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.2174\/1381612825666191009161018","article-title":"Switching from Conventional to Nano-natural Phytochemicals to Prevent and Treat Cancers: Special Emphasis on Resveratrol","volume":"25","author":"Salman","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"ref_457","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1208\/s12248-019-0325-y","article-title":"Targeting Cancer Via Resveratrol-Loaded Nanoparticles Administration: Focusing on In Vivo Evidence","volume":"21","author":"Santos","year":"2019","journal-title":"AAPS J."},{"key":"ref_458","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1007\/s43440-020-00073-7","article-title":"Curcumin augments therapeutic efficacy of TRAIL-based immunotoxins in leukemia","volume":"72","author":"Surapally","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"ref_459","doi-asserted-by":"crossref","first-page":"16857","DOI":"10.1021\/acsami.7b02863","article-title":"Novel Curcumin Liposome Modified with Hyaluronan Targeting CD44 Plays an Anti-Leukemic Role in Acute Myeloid Leukemia in Vitro and in Vivo","volume":"9","author":"Sun","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_460","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/s12935-022-02673-0","article-title":"A systematic review of anti-cancer roles and mechanisms of kaempferol as a natural compound","volume":"22","author":"Amjad","year":"2022","journal-title":"Cancer Cell Int."},{"key":"ref_461","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1002\/ptr.7386","article-title":"Wogonin and its analogs for the prevention and treatment of cancer: A systematic review","volume":"36","author":"Banik","year":"2022","journal-title":"Phytother. Res."},{"key":"ref_462","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0223-5234(97)84363-2","article-title":"Synthesis and in vitro cytotoxicity of a series of 3-aminoflavones","volume":"32","author":"Dauzonne","year":"1997","journal-title":"Eur. J. Med. Chem."},{"key":"ref_463","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00706-006-0550-9","article-title":"Efficient Synthesis of Nitroflavones by Cyclodehydrogenation of 20-Hydroxychalcones and by the Baker-Venkataraman Method","volume":"137","author":"Barros","year":"2006","journal-title":"Monatshefte F\u00fcr Chem."},{"key":"ref_464","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1016\/j.bmc.2005.12.021","article-title":"Antitumor activity of some natural flavonoids and synthetic derivatives on various human and murine cancer cell lines","volume":"14","author":"Cardenas","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"ref_465","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/bs.acr.2019.01.005","article-title":"Pharmacology of ME-344, a novel cytotoxic isoflavone","volume":"142","author":"Zhang","year":"2019","journal-title":"Adv. Cancer Res."},{"key":"ref_466","doi-asserted-by":"crossref","first-page":"716s","DOI":"10.1093\/jn\/136.3.716S","article-title":"Clarifying the real bioactive constituents of garlic","volume":"136","author":"Amagase","year":"2006","journal-title":"J. Nutr."},{"key":"ref_467","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.chroma.2005.12.016","article-title":"The analysis of onion and garlic","volume":"1112","author":"Lanzotti","year":"2006","journal-title":"J. Chromatogr. A"},{"key":"ref_468","doi-asserted-by":"crossref","unstructured":"Khanam, S., Mishra, P., Faruqui, T., Alam, P., Albalawi, T., Siddiqui, F., Rafi, Z., and Khan, S. (2025). Plant-based secondary metabolites as natural remedies: A comprehensive review on terpenes and their therapeutic applications. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1587215"},{"key":"ref_469","doi-asserted-by":"crossref","unstructured":"Li, F., Gao, C., Li, X., Wang, J., Zhao, Y., Ke, Y., Liu, Y., Liu, H.M., Hu, Z., and Wei, L. (2022). Jiyuan oridonin A induces differentiation of acute myeloid leukemia cells including leukemic stem-like cells. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1001552"},{"key":"ref_470","doi-asserted-by":"crossref","unstructured":"Chen, L., Li, D., Guo, X., Cheng, C., and Wei, X. (2023). Oridonin Synergistically Enhances the Pro-Apoptotic Effect of Venetoclax on Acute Myeloid Leukemia Cells by Inhibiting AKT Signaling. Front. Biosci. (Landmark Ed.), 28.","DOI":"10.31083\/j.fbl2809195"},{"key":"ref_471","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/156800913804486601","article-title":"Mechanistic insights into the antileukemic activity of hyperforin","volume":"13","author":"Billard","year":"2013","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_472","doi-asserted-by":"crossref","unstructured":"Menegazzi, M., Masiello, P., and Novelli, M. (2020). Anti-Tumor Activity of Hypericum perforatum L. and Hyperforin through Modulation of Inflammatory Signaling, ROS Generation and Proton Dynamics. Antioxidants, 10.","DOI":"10.3390\/antiox10010018"},{"key":"ref_473","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/ijc.24295","article-title":"Hyperforin and aristoforin inhibit lymphatic endothelial cell proliferation in vitro and suppress tumor-induced lymphangiogenesis in vivo","volume":"125","author":"Rothley","year":"2009","journal-title":"Int. J. Cancer"},{"key":"ref_474","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Poveda, B., Verotta, L., Bombardelli, E., Quesada, A.R., and Medina, M.A. (2010). Tetrahydrohyperforin and octahydrohyperforin are two new potent inhibitors of angiogenesis. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0009558"},{"key":"ref_475","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1021\/acs.molpharmaceut.9b01051","article-title":"Improved Bioactivity of the Natural Product 5-Lipoxygenase Inhibitor Hyperforin by Encapsulation into Polymeric Nanoparticles","volume":"17","author":"Traeger","year":"2020","journal-title":"Mol. Pharm."},{"key":"ref_476","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1517\/17425247.5.6.653","article-title":"Drug delivery in acute myeloid leukemia","volume":"5","author":"Michelfelder","year":"2008","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_477","doi-asserted-by":"crossref","first-page":"e2403409","DOI":"10.1002\/smll.202403409","article-title":"Advances in Drug Delivery Systems for the Treatment of Acute Myeloid Leukemia","volume":"20","author":"Wu","year":"2024","journal-title":"Small"},{"key":"ref_478","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/CCO.0000000000001090","article-title":"The emerging role of melflufen and peptide-conjugates in multiple myeloma","volume":"36","author":"Moukalled","year":"2024","journal-title":"Curr. Opin. Oncol."},{"key":"ref_479","doi-asserted-by":"crossref","unstructured":"Jia, W., Zhou, L., Li, L., Zhou, P., and Shen, Z. (2023). Nano-Based Drug Delivery of Polyphenolic Compounds for Cancer Treatment: Progress, Opportunities, and Challenges. Pharmaceuticals, 16.","DOI":"10.3390\/ph16010101"},{"key":"ref_480","doi-asserted-by":"crossref","first-page":"377","DOI":"10.5114\/bta.2024.145258","article-title":"Quercetin nanoparticles as a therapeutic approach: Pharmacological actions and potential applications in therapy","volume":"105","author":"Baiomy","year":"2024","journal-title":"Biotechnologia"},{"key":"ref_481","doi-asserted-by":"crossref","unstructured":"Kazmi, I., Al-Abbasi, F.A., Afzal, M., Altayb, H.N., Nadeem, M.S., and Gupta, G. (2021). Formulation and Evaluation of Kaempferol Loaded Nanoparticles against Experimentally Induced Hepatocellular Carcinoma: In Vitro and In Vivo Studies. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13122086"},{"key":"ref_482","doi-asserted-by":"crossref","unstructured":"Pandey, P., Khan, F., Alshammari, N., Saeed, A., Aqil, F., and Saeed, M. (2023). Updates on the anticancer potential of garlic organosulfur compounds and their nanoformulations: Plant therapeutics in cancer management. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1154034"},{"key":"ref_483","doi-asserted-by":"crossref","first-page":"993","DOI":"10.7150\/thno.104872","article-title":"Metformin-based nanomedicines for reprogramming tumor immune microenvironment","volume":"15","author":"Liu","year":"2025","journal-title":"Theranostics"},{"key":"ref_484","doi-asserted-by":"crossref","first-page":"142486","DOI":"10.1016\/j.ijbiomac.2025.142486","article-title":"Hyaluronic acid-functionalized nanomedicines for CD44-receptors-mediated targeted cancer therapy: A review of selective targetability and biodistribution to tumor microenvironment","volume":"308","author":"Haider","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_485","doi-asserted-by":"crossref","unstructured":"Serini, S., Trombino, S., Curcio, F., Sole, R., Cassano, R., and Calviello, G. (2023). Hyaluronic Acid-Mediated Phenolic Compound Nanodelivery for Cancer Therapy. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15061751"},{"key":"ref_486","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1080\/10717544.2017.1384864","article-title":"Targeted inhibition of human hematological cancers in vivo by doxorubicin encapsulated in smart lipoic acid-crosslinked hyaluronic acid nanoparticles","volume":"24","author":"Zhong","year":"2017","journal-title":"Drug Deliv."},{"key":"ref_487","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem Cell"},{"key":"ref_488","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-021-01416-w","article-title":"Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia","volume":"36","author":"Himonas","year":"2022","journal-title":"Leukemia"},{"key":"ref_489","doi-asserted-by":"crossref","unstructured":"Addanki, S., Kim, L., and Stevens, A. (2025). Understanding and Targeting Metabolic Vulnerabilities in Acute Myeloid Leukemia: An Updated Comprehensive Review. Cancers, 17.","DOI":"10.3390\/cancers17081355"},{"key":"ref_490","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1038\/s41375-024-02326-3","article-title":"CXCR4 as a therapeutic target in acute myeloid leukemia","volume":"38","author":"Korbecki","year":"2024","journal-title":"Leukemia"},{"key":"ref_491","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/bph.16149","article-title":"Targeting integrins in drug-resistant acute myeloid leukaemia","volume":"181","author":"Ogana","year":"2024","journal-title":"Br. J. Pharmacol."},{"key":"ref_492","doi-asserted-by":"crossref","first-page":"22062","DOI":"10.1038\/s41598-021-01300-8","article-title":"Targeting CD38 in acute myeloid leukemia interferes with leukemia trafficking and induces phagocytosis","volume":"11","author":"Farber","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_493","doi-asserted-by":"crossref","unstructured":"Matthews, A.H., Pratz, K.W., and Carroll, M.P. (2022). Targeting Menin and CD47 to Address Unmet Needs in Acute Myeloid Leukemia. Cancers, 14.","DOI":"10.3390\/cancers14235906"},{"key":"ref_494","doi-asserted-by":"crossref","unstructured":"Pelosi, E., Castelli, G., and Testa, U. (2023). CD123 a Therapeutic Target for Acute Myeloid Leukemia and Blastic Plasmocytoid Dendritic Neoplasm. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032718"},{"key":"ref_495","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"key":"ref_496","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12032-025-02721-5","article-title":"Pterostilbene as a Multifaceted Anticancer Agent: Molecular Mechanisms, Therapeutic Potential and Future Directions","volume":"42","author":"Ali","year":"2025","journal-title":"Med. Oncol."},{"key":"ref_497","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.phrs.2017.08.010","article-title":"Targeting NAD(+) degradation: The therapeutic potential of flavonoids for Alzheimer\u2019s disease and cognitive frailty","volume":"128","author":"Ruan","year":"2018","journal-title":"Pharmacol. Res."},{"key":"ref_498","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.2337\/db12-1139","article-title":"Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: Implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome","volume":"62","author":"Escande","year":"2013","journal-title":"Diabetes"},{"key":"ref_499","first-page":"461","article-title":"[Inflammatory cytokines and oxidative stress markers in the inhibition of osteoarthritis by curcumin]","volume":"45","author":"Liu","year":"2016","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"ref_500","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1021\/acsnano.4c12131","article-title":"Multifunctional Nanomedicine for Targeted Atherosclerosis Therapy: Activating Plaque Clearance Cascade and Suppressing Inflammation","volume":"19","author":"Tang","year":"2025","journal-title":"ACS Nano"},{"key":"ref_501","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2174\/1567201819666220823155526","article-title":"Nanoformulations of Plant-Derived Compounds as Emerging Therapeutic Approach for Colorectal Cancer","volume":"20","author":"Biganeh","year":"2023","journal-title":"Curr. Drug Deliv."},{"key":"ref_502","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s11899-015-0255-4","article-title":"Targeting the microenvironment in acute myeloid leukemia","volume":"10","author":"Rashidi","year":"2015","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_503","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1158\/2643-3230.BCD-23-0202","article-title":"Recent Advances in Immune-Based Therapies for Acute Myeloid Leukemia","volume":"5","author":"Restelli","year":"2024","journal-title":"Blood Cancer Discov."},{"key":"ref_504","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/14712598.2025.2479014","article-title":"A review of antibody-based immunotherapy clinical trials for adult acute myeloid leukemia (AML): Monoclonal antibodies (mAbs) and beyond","volume":"25","author":"Dykes","year":"2025","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_505","doi-asserted-by":"crossref","unstructured":"Halik, A., Arends, C.M., Bullinger, L., Damm, F., and Frick, M. (2022). Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents. Cancers, 14.","DOI":"10.3390\/cancers14071689"},{"key":"ref_506","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1038\/s41375-025-02756-7","article-title":"Clonal evolution and apoptosis resistance in myelodysplastic neoplasms and acute myeloid leukemia under treatment: Insights from integrative longitudinal profiling","volume":"39","author":"Mazzeo","year":"2025","journal-title":"Leukemia"},{"key":"ref_507","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s12015-021-10308-6","article-title":"Acute Myeloid Leukemia Stem Cells: Origin, Characteristics, and Clinical Implications","volume":"18","author":"Long","year":"2022","journal-title":"Stem Cell Rev. Rep."},{"key":"ref_508","doi-asserted-by":"crossref","unstructured":"Niu, J., Peng, D., and Liu, L. (2022). Drug Resistance Mechanisms of Acute Myeloid Leukemia Stem Cells. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.896426"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/2\/185\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:40:16Z","timestamp":1767703216000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/2\/185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":508,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["cancers18020185"],"URL":"https:\/\/doi.org\/10.3390\/cancers18020185","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]}}}